

Summit 2023

Dementia in a new era:
prevent, diagnose, treat



**World Dementia
Council** Leading the Global Action
Against Dementia

Biographies



Alzheimer's
Drug Discovery
Foundation

25
YEARS

Hosts

Philip Scheltens

Professor of Cognitive Neurology and Director Alzheimer Center, University of Amsterdam Medical Centers
Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He became Professor of Cognitive Neurology and founder of the Alzheimer Center at Amsterdam University Medical Centers in 2000, which he directed until 2022. Currently he devotes most of time heading the Dementia Fund at EQT Life Sciences, that he started in 2020. He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >75 PhD theses since 2000. He founded the Dutch national plan against dementia and served as chair of the board. He is co-editor-in-chief of Alzheimer's Research & Therapy and co-leads various EU projects. He authored over 1100 peer reviewed papers and > 75 book chapters and co-edited several major textbooks. He is member of the Royal Dutch Academy of Arts and Sciences (KNAW) since 2011. In 2016 he was awarded the European Grand Prix for Alzheimer's Research. In 2020 he was Knighted in the Order of the Netherlands Lion by the King of the Netherlands. In 2021 he was elected honorary member of the European Academy of Neurology and was appointed chair of the World Dementia Council.

Kiyoshi Kurokawa

Chairman Health and Global Policy Institute (HGPI)
Dr. Kiyoshi Kurokawa is a graduate of the University of Tokyo Faculty of Medicine. From 1969 to 1984, he lived in the United States where he served as Professor of Internal Medicine at the University of California, Los Angeles (UCLA) School of Medicine. His other positions have included Professor of Internal Medicine, University of Tokyo; Dean, School of Medicine, Tokai University; President, Science Council of Japan (2003-2006); Member, Council for Science and Technology Policy, Cabinet Office (2003-2006); Special Advisor, Cabinet Office (2006-2008); and Commissioner, World Health Organization (WHO) (2005-2009). He also served as Chairman of the National Diet of Japan's Fukushima Nuclear Accident Independent Investigation Commission (December 2011-July 2012), Chair and Representative Director of the Global Health Innovative Technology Fund (GHIT Fund) (January 2013-June 2018), and as Special Advisor on Health and Medical Strategy at the Cabinet Secretariat Headquarters for Healthcare and Medical Strategy Promotion (2013-2019). Dr. Kurokawa's current positions include Vice Chair and Committee Member of the World Dementia Council (WDC) and Chairman of the Investigative Committee on AI Simulation for Coronavirus Disease 2019 Countermeasures. He has been named professor emeritus at the National Graduate Institute for Policy Studies (GRIPS) and the University of Tokyo and as a Distinguished Professor of Tokai University.

Lenny Shallcross

Executive Director World Dementia Council

Lenny Shallcross is Executive Director of the World Dementia Council. Prior to leading the World Dementia Council Lenny held senior policy and advocacy roles at the Alzheimer's Society in the UK. He worked in the UK government as a special adviser at the Department for Culture, Media and Sport and the Department of Health as well as working in Parliament and for the Labour Party. Lenny read medicine and history at Cambridge University.

Speakers

- Ricardo Allegri** Director of the Ageing and Memory Centre Fleni Neurological Institute
- Paola Barbarino** CEO Alzheimer's Disease International (ADI)
- Laurence Barker** Chief Finance Officer Dementia Discovery Fund (DDF)
- Phyllis Barkman Ferrell** Global Head of External Engagement for Alzheimer's Disease and Neurodegeneration Eli Lilly
- Matthew Baumgart** Senior Director of Public Policy Alzheimer's Association
- Howard Bergman** Professor of Family Medicine, Geriatric Medicine and Oncology McGill University
- Alistair Burns** Professor of Old Age Psychiatry NHS England Dept Health Lead
- Fiona Carragher** Chief Research and Policy Officer Alzheimer's Society
- Tarun Dua** Unit Head, Brain Health World Health Organization (WHO)
- Karen Duff** Professor and Director, UK DRI Hub Dementia Research Institute (DRI) University College London
- Howard Fillit** Co-Founder and Chief Science Officer Alzheimer's Drug Discovery Foundation (ADDF)
- George Freeman MP** Minister of State Department for Science, Innovation and Technology
- Giovanni Frisoni** Clinical Neurologist, Full Professor of Clinical Neuroscience Geneva University
- Laurence Geller** Chairman Geller Capital Partners
- John Harrison** Chief Scientific Officer Scottish Brain Sciences
- Miia Kivipelto** Professor in Clinical Geriatrics Karolinska Institutet
- Anja Leist** Associate Professor in Public Health and Ageing and Vice-Head of the Institute for Research on Socio-Economic Inequality at the University of Luxembourg
- Gillian Leng** Chief Executive National Institute for Health and Care Excellence (NICE)
- Mark McClellan** Professor of Business, Medicine, and Health Duke University Mark McClellan, MD, PhD, is Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Policy at the Margolis Center for Health Policy at Duke University
- Brad O'Connor** CEO Cogstate
- William Reichman** President and CEO Baycrest Health Sciences Center
- Heather Snyder** Vice President, Medical & Scientific Relations Alzheimer's Association
- Johannes Streffer** CMO AC Immune
- Ivonne Suridjan** Director, Global Clinical Development & Neurology Indication Leader Roche
- Charlotte Teunissen** Professor of Clinical Chemistry Amsterdam University Medical Center
- Arthur Toga** Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences University of Southern California (USC)
- Andrew Trister** Deputy Director, Health Artificial Intelligence Bill & Melinda Gates Foundation
- Jetske van der Schaar** PHD Researcher University of Amsterdam
- Ernst van Koesveld** Director General Longterm Care Government of Netherlands
- George Vradenburg** Co-Chair Davos Alzheimer's Collaborative
- Caleb Webber** Director of Informatics and Data Science for the UK Dementia Research Institute Dementia Research Institute (DRI)
- Stacie Weninger** President Foundation for Biomedical Research and Innovation (FBRI)

Ricardo Allegri Director of the Ageing and Memory Centre Fleni Neurological Institute

Dr. Ricardo F. Allegri is Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Memory and Ageing Center at the Neurological Research Institute Fleni, Buenos Aires, Argentina. He is Professor of Neurology in the School of Medicine at the University of Buenos Aires, and Superior Researcher from CONICET (National Agency of Research from Argentina). He has chaired the Buenos Aires Health Research Council from 2008-2014 and from 2020 until today. Dr Allegri has working extensively in Latin America on cognitive neurosciences and dementia and nowadays he is PI in Argentina from DIAN (Dominantly Inherited Alzheimer Network), and LatAm-FINGER (Latin American FINGER Project). Professor Allegri is Fellow of the American Academy of Neurology, chair of the Scientific Council at the Argentine Association against Alzheimer's disease (ALMA), Member at the medical advisory of Alzheimer Disease International and Council Member and Trustee of the World Dementia Council.

Paola Barbarino CEO Alzheimer's Disease International (ADI)

Paola is CEO of ADI. Prior to this, she was CEO of LIFE and occupied senior positions with Cass Business School, Tate, British Library and IIED. Previously she was a Non-Executive Director of the Non-Communicable Disease Alliance (NCDA), a Trustee of Shelter, the housing/homelessness charity, and of MLA London. She holds a degree cum laude in Classics from Federico II Napoli University, an MA in Field and Analytical Techniques in Archaeology and an MA in Library and Information Science both from University College London. Paola leads on all aspects of ADI's work. Together with the Board, Paola ensures our strategy is implemented and resourced. Paola is ADI's main spokesperson and represents the organisation internationally.

Laurence Barker Chief Finance Officer Dementia Discovery Fund (DDF)

Laurence is a Partner in the Dementia Discovery Fund (DDF) and has supported the funding and formation of numerous DDF companies developing transformational new medicines for dementia. He joined SV Health Investors in 2016 having played an active role in setting up DDF. Prior to joining the DDF, Laurence was Head of Investment Management in Worldwide Business Development at GSK where he was responsible for managing GSK's venture investment portfolio, covering both direct equity positions as well as a venture fund-of-funds portfolio. In addition, he led licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at biotech companies Syntaxin and MorphoSys. Laurence received his Masters degree in Biochemistry and Molecular Biology from the University of Auckland, New Zealand, his PhD in Biochemistry from the University of Tübingen, Germany, and an MBA from Cambridge.

Phyllis Barkman Ferrell Global Head of External Engagement for Alzheimer's Disease and Neurodegeneration Eli Lilly

Phyllis Ferrell is the Global Head of External Engagement for Alzheimer's disease at Eli Lilly & Company. She also currently serves on secondment as the Director of the Davos Alzheimer's Collaborative Healthcare System Preparedness initiative. Phyllis has a BA in Economics from DePauw University and an MBA from Stanford University. Phyllis is a current member of the World Dementia Council, a steering committee member of the Milken Institute Center for Aging Alliance for Dementia Care, and a strategic reviewer for the Alzheimer's Disease Drug Discovery Foundation Diagnostics Accelerator. Phyllis is also on the Boards of Directors for Alzheimer's Research UK EDoN, Gates Ventures Alzheimer's Disease Data Initiative, the Indiana Chapter of the Alzheimer's Association, and the Indianapolis 500 Festival. Phyllis is a founding member of Women Against Alzheimer's and Women of Impact Boone County; co-chair of the Women's Leadership Council and the alumna sponsor of the Women in Economics and Business Program at DePauw University. Phyllis is passionate about Alzheimer's advocacy and brain health so that other boys don't have to grow up without their grandfathers' presence as her sons did.

Matthew Baumgart Senior Director of Public Policy Alzheimer's Association

Matthew Baumgart is Vice President of Health Policy for the U.S. Alzheimer's Association, leading a range of projects at the intersection of policy and programs to achieve an aggressive agenda that serves all those affected by the disease. In this role, he heads the Public Health Center of Excellence on Dementia Risk Reduction, funded by the Centers for Disease Control and Prevention. In addition, Baumgart directs the Association's global public policy efforts, working in collaboration with Alzheimer's Disease International, the World Dementia Council, and the World Health Organization. Baumgart joined the Alzheimer's Association in 2009 and has served in roles overseeing policy development, public health policy initiatives, federal affairs, and state governmental affairs. Prior to joining the Association, Baumgart spent nearly 20 years working in the United States Senate, including as legislative director for Senator Barbara Boxer of California and legislative assistant for over a decade to Senator Joe Biden. Baumgart has a degree in communications with a second major in political science from Washington State University.

Howard Bergman Professor of Family Medicine, Geriatric Medicine and Oncology McGill University
Howard Bergman, MD, FCFP, FRCPC, FCAHS, is professor of Family Medicine, Medicine and Oncology and Assistant Dean, International Affairs, Faculty of Medicine, McGill University. He was Chair of the Department of Family Medicine (2012-2019), the inaugural Dr. Joseph Kaufmann Professor of Geriatric Medicine (2001-2015). He is a Fellow of the Canadian Academy of Health Sciences (CAHS) and of the College of Family Physicians of Canada and of the Royal College of Physicians and Surgeons of Canada. He is internationally renowned for research which has influenced policy change in primary care and aging, with over 190 peer-reviewed publications. Dr Bergman has extensive experience in health policy and implementation. In 2000, as a member of the Quebec Government Commission, he authored the recommendation creating the medical home in Quebec. In 2009, he authored the Quebec Alzheimer Plan and works with the government on its implementation. In 2019, he chaired the CAHS Expert Panel for the development of a Canadian Dementia Strategy, at the request of Public Health Agency of Canada. He co-leads the Canadian Team for healthcare services/system improvement in dementia care (ROSA research team). Dr. Bergman is one of 24 members of the World Dementia Council.

Alistair Burns Professor of Old Age Psychiatry NHS England
Dept Health Lead

Alistair Burns is Professor of Old Age Psychiatry at The University of Manchester and an Honorary Consultant Old Age Psychiatrist in the Greater Manchester Mental Health NHS Foundation Trust. He is Director of the Manchester Institute for Collaborative Research on Ageing (MICRA) and the National Clinical Director for Dementia and Older People's Mental Health at NHS England and NHS Improvement. He graduated in medicine from Glasgow University in 1980, training in psychiatry at the Maudsley Hospital and Institute of Psychiatry in London. He became the Foundation Chair of Old Age Psychiatry in The University of Manchester in 1992, where he has variously been Head of the Division of Psychiatry and a Vice Dean in the Faculty of Medical and Human Sciences, with responsibility for liaison within the NHS. He set up the Memory Clinic in Manchester and helped establish the old age liaison psychiatry service at Wythenshawe Hospital. He is a Past President of the International Psychogeriatric Association. He was Editor of the International Journal of Geriatric Psychiatry for twenty years, (retiring in 2017) and is on the Editorial Boards of the British Journal of Psychiatry and International Psychogeriatrics. His research and clinical interests are in mental health problems of older people, particularly dementia and Alzheimer's disease. He has published nearly 400 papers and 25 books in the field of mental health and dementia. He was made an honorary fellow of the Royal College of Psychiatrists in 2016, received the lifetime achievement award from their old age Faculty in 2015 and was awarded the CBE in 2016 for contributions to health and social care, in particular dementia.

Fiona Carragher Chief Research and Policy Officer
Alzheimer's Society

Fiona Carragher joined Alzheimer's Society as Executive Director of Research and Influencing in January 2019. She plays a pivotal role at the Society as we aim to be a leading force for change and use research and influencing to push for breakthroughs that will improve the lives of people affected by dementia now and in the future. Driving evidence-based policy making and connecting science and research into practise has underpinned her career. Before joining Alzheimer's Society Fiona was the Deputy Chief Scientific Officer for NHS England providing leadership for the 50,000 healthcare science professionals in the NHS and expert advice to the health system on science, innovation, and diagnostics. She led a broad portfolio of policy responsibilities including establishing the UK Antimicrobial Resistance Diagnostics programme, the system wide Action Plan on Hearing Loss and the CSO Knowledge Transfer Partnership programme. She is a passionate advocate for women in health and led the establishment of the first Women in Science and Engineering fellowship programme in the NHS.

Tarun Dua Unit Head, Brain Health World Health
Organization (WHO)

I am the Unit Head of Brain Health Unit in the Department of Mental Health and Substance Use at World's Health Organization Headquarters. The aim of the unit is to promote optimal brain development, cognitive health and wellbeing for all, and prevention and management of neurological disorders across the life-course. The unit is responsible for coordinating the implementation of the intersectoral action plan on epilepsy and other neurological disorders as well as the specific global action plan on public health response to dementia.

Karen Duff Professor and Director, UK DRI Hub
Dementia Research Institute (DRI) University College
London

Professor Duff is the Centre Director of the UK Dementia Research Institute at University College London and Professor Emerita and Special Lecturer at the department of Pathology at Columbia University Medical Center, New York. She received her PhD from Sydney Brenner's department at the University of Cambridge in 1991. She undertook postdoc positions in London with Alison Goate from 1991-1992, and John Hardy at the University of South Florida from 1992-1994. She was an Assistant Professor at the University of South Florida from 1993-1996, Associate Professor at Mayo Clinic Jacksonville from 1996-1998, and Professor at the New York University Nathan Kline Institute from 1998-2006 followed by Columbia University from 2006-2019 where she was deputy director of the Taub Institute. Professor Duff explores disease mechanisms and test therapeutic approaches to Alzheimer's disease, FTD and other dementias. Her current interests are exploring the mechanisms involved in the spread of pathogenic proteins within the brain, understanding the basis of selective cellular vulnerability and resilience to tauopathy and developing new mouse and cell models to understand the earliest stages in tau pathogenesis. Professor Duff has published 140 peer-reviewed research articles and received several prizes including the Potemkin Prize in 2006 and most recently the British Neuroscience Association award for Outstanding Contribution to Neuroscience in 2020 and Fellowship of the UK Academy of Medical Sciences in 2022.

Howard Fillit Co-Founder and Chief Science Officer
Alzheimer's Drug Discovery Foundation (ADDF)

Howard Fillit, MD, is a geriatrician, neuroscientist, and innovative philanthropy executive, who has led the Alzheimer's Drug Discovery Foundation since its founding. Dr. Fillit has held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. In 1987, he joined the Mount Sinai School of Medicine, where he is a clinical professor of geriatric medicine and palliative care, medicine and neuroscience. Dr. Fillit also maintains a limited private practice in consultative geriatric medicine with a focus on Alzheimer's disease and related dementias. He has authored or co-authored more than 350 publications and is the senior editor of Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Dr. Fillit is the recipient of many awards and honors including the Rita Hayworth Award from the Alzheimer's Association. He is a fellow of the American Geriatrics Society, the American College of Physicians, the Gerontological Society of America and the New York Academy of Medicine. Dr. Fillit earned his Bachelor of Arts in neurobiology cum laude from Cornell University and his medical degree from the SUNY-Upstate Medical University.

George Freeman Minister of State Department for
Science, Innovation and Technology

George Freeman MP for Mid Norfolk Minister of State for Science, Research & Innovation at the Department for Science, Innovation and Technology. George was elected to Parliament in 2010 after a 15 year career founding, financing and managing high growth technology start-ups in the biotech, agritech & cleantech sectors. He has served in various frontline Ministerial roles since 2010: as the UK's first Minister for Life Science in the Coalition, where he led the UK Life Science & Agritech Industrial Strategies & launched the £100k Genomics & Catalyst Funding program; Minister of State for the Future of Transport; and Minister for Science, Technology & Innovation responsible for UK technology strategy, Space, Fusion, launching ARIA and leading the PM's Task Force on Innovation, Growth and Regulatory Reform (TIGRR). Founder of the One Nation Conservative Caucus, the Reform for Resilience Global Health Commission, the Big Tent Ideas Festival and the 2020 Conservatives Group, author of Britain Beyond Brexit and former Chair of the Prime Minister's Policy Board and Conservative Policy Forum.

Giovanni Frisoni Clinical Neurologist, Full Professor
of Clinical Neuroscience Geneva University Hospitals
Clinical neurologist, Full Professor of Clinical
Neuroscience at the University of Geneva. Switzerland,
and Director of the Memory Clinic of the Geneva
University Hospital

Former Scientific Director at the National Alzheimer's Centre in Brescia, Italy. Author of over 700 scientific papers listed in PubMed, imaging editor for Neurobiology of Aging, and founding editorial board member of The Lancet Neurology. Has led national and international projects funded by the European Commission, IMI, the Alzheimer's Association, Italian and Swiss Ministry of Health, and industry. Chairman of Alzheimer's Imaging Consortium at International Conference on Alzheimer's Disease in 2010 and 2011. Honorary member of the Austrian Neurological Society and of the French Society of Neurology, he has received the Investigator Award Winner of European Academy of Neurology in 2016.

Laurence Geller Chairman Geller Capital Partners

Since founding his first hotel in 1989, Laurence Geller CBE has built a global hospitality empire. Geller lost his parents to dementia and has since devoted his life to the prevention, treatment, and care of this condition. Geller has built a collection of world-leading dementia care facilities while funding innovation and research to bring residents the highest level of care and comfort. As Founder and Chairman of Loveday & Co, Geller has coordinated private, public, academic, and philanthropic partners to create a world-leading provider of specialist dementia care. Loveday & Co have been recognized as pioneers of dementia care, winning the 'Best for Nursing Care' award in 2019, 2021 and 2022, overall Gold trophy for 'Best Individual Care Home' in 2021. Loveday 'Loveday Chelsea Court Palace' has received an 'Outstanding Rating' by CQC. Geller is the Department for Digital, Culture, Media and Sport's Ministerial Adviser for Concussion in Sport (2021 -). As part of this responsibility Geller has worked to establish the UK as the global centre on concussion in sport and related neurodegeneration. He has coordinated his network among leading sport and medical experts in the UK, US, Canada, Switzerland. As Chancellor of the University of West London (UWL), Geller funds and oversees major life sciences projects through the Geller Institute for Ageing and Memory (GIAM), launched in June 2020 at UWL. GIAM has already secured £1.429 million of external funding, rising to £3.3 million when current bids are evaluated. Life sciences projects led by GIAM, include multisensory culture boxes to promote public health guidance and to support the wellbeing of people with dementia in care homes.

John Harrison Chief Scientific Officer Scottish Brain
Sciences

Professor John Harrison is an acknowledged cognition expert whose principal professional interest is in helping people understand, maintain, and enhance their cognitive skills. He is Chief Scientific Officer at Scottish Brain Sciences practice where advises on the selection and successful integration of cognitive testing into therapeutic development programs. John is an Associate Professor with the AUMc Alzheimer Center and Visiting Professor at King's College London. He holds Chartered Psychologist status and has authored/co-authored more than 100 books and scientific articles, including a popular neuroscience book 'Synaesthesia: The Strangest Thing'. John's wider professional activities include conference hosting, professional voiceover acting and podcasting.

Miia Kivipelto Professor in Clinical Geriatrics Karolinska Institutet

Miia Kivipelto, MD, PhD, is Professor of Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research, and senior geriatrician and Director for Research & Development of Theme Aging at Karolinska University Hospital, Stockholm, Sweden. Her frontline research findings have been published in leading journals (400+ publications, H-index 83) and she has received numerous prestigious national and international awards. Dr. Kivipelto's translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer's disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. Professor Kivipelto is the PI of the landmark FINGER Randomized Controlled Trial (RCT) (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability), which is the first large-scale trial showing that a multi-domain lifestyle based intervention can reduce the risk of cognitive and functional impairment among at risk persons from general population. This pragmatic model is now tested and adapted worldwide and Professor Kivipelto has launched the World Wide FINGERS network, a unique interdisciplinary network to share experiences, harmonise data, and plan joint international initiatives for the prevention of cognitive impairment/dementia (45 countries currently involved).

Anja Leist Co-chair World Young Leaders in Dementia
Anja Leist is Associate Professor in Public Health and Ageing and Vice-Head of the Institute for Research on Socio-Economic Inequality at the University of Luxembourg

After her PhD studies in Psychology at the University of Trier, she had postdoctoral research stays at the universities of Luxembourg, Zurich, and Rotterdam. Her research focuses on cognitive ageing and dementia from a social and behavioural (risk reduction) perspective. Anja's research interests also involve social and life-course determinants of health, healthcare use, and use of technology at older ages. Anja is PI of several competitively funded research projects, among them a grant from the European Research Council on cognitive ageing and dementia with a focus on lifestyle behaviours and contextual inequalities related to education and gender. She is co-leading an interdisciplinary flagship project at her institution that investigates links between the social environment, microbiome, and dementia. Anja has received an 'innovative publication' award, is elected Fellow of the Gerontological Society of America, and co-founder of the World Young Leaders in Dementia a.s.b.l. (WYLD) network, now a registered non-profit organization facilitating careers of young professionals in dementia. She is member of several steering groups and scientific advisory boards. Anja is a Rotarian, married, and has two children.

Gillian Leng Chief Executive National Institute for Health and Care Excellence (NICE)

Gillian Leng spent over 20 years in senior roles at the National Institute for Health and Care Excellence, becoming only its second Chief Executive. She published a new 5 year strategy for the organisation aiming to put NICE at the forefront of evaluating new medicines, devices and diagnostics, and delivering dynamic, living guidelines. Gillian has close knowledge of the health and care system, both as a frontline clinician and through her work to improve patient access to effective new treatments and interventions. She has worked closely with government on new policy developments, including the Office for Life Sciences, BEIS, DHSC, the Department for Education and the What Works Centres. Gillian trained in medicine at Leeds, worked on clinical trials and epidemiological research in Edinburgh, and was a public health consultant in London. She is now the Dean at the Royal Society of Medicine, on the Board of Radar Healthcare and a trustee of the Cochrane Collaboration and the Guidelines International Network. She is also a visiting professor at King's College London and an affiliate professor at the National University of Singapore.

Mark McClellan Professor of Business, Medicine, and Health Duke University
Mark McClellan, MD, PhD, is Director and Robert J. Margolis, M.D., Professor of Business, Medicine and Policy at the Margolis Center for Health Policy at Duke University

He is a physician-economist who focuses on quality and value in health care, including payment reform, real-world evidence and more effective drug and device innovation. Dr. McClellan is at the center of the nation's efforts to combat the pandemic and the author of a roadmap that details the steps needed for a comprehensive COVID-19 response and safe reopening of our country. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. Dr. McClellan is an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and serves as an advisor for Arsenal Capital Group, Blackstone Life Sciences, and MITRE.

Brad O'Connor CEO Cogstate

Since 2005, I've served as CEO of Cogstate, helping lead our work to drive access and equity in brain health by building tools that help everyone measure and understand the health of their brain. Previously, I had a career in finance, which included a number of years in the Tax and Legal services group of PricewaterhouseCoopers, before accepting the role as CFO and Company Secretary of Cogstate in 2004. I originally joined Cogstate to help keep the company afloat—and the hard work and passion of my colleagues has kept me around for decades.

William Reichman President and CEO Baycrest Health Sciences Center

Dr. William E. Reichman is President and Chief Executive Officer of Baycrest, among the world's premier academic health care organizations focused on seniors' health and residential care and aging brain function. Dr. Reichman has an appointment as Professor of Psychiatry on the Faculty of Medicine at the University of Toronto and is a recipient of an honorary degree of laws from OCAD University. He is a noted global authority on the delivery of innovative medical, mental health and dementia services in geriatric care settings. Dr. Reichman is a former President of the International Psychogeriatric Association, the American Association for Geriatric Psychiatry, and the Geriatric Mental Health Foundation. He has been a special consultant to the Civil Rights Division of the United States Department of Justice on dementia and mental health-care delivery within nursing homes and has advised the WHO and the governments of Canada and China on health policy. He served as the weekly Senior Health columnist for the Star Ledger, New Jersey's highest circulation newspaper and has been widely interviewed and quoted by all of the major media outlets in the United States and Canada. Recently, he also served as Co-Chair of Canada's Ministerial Advisory Board on Dementia and was instrumental in the development of Canada's National Dementia Strategy.

Heather Snyder Vice President, Medical & Scientific Relations Alzheimer's Association

Heather M. Snyder, Ph.D., is vice president, Medical & Scientific Relations at the Alzheimer's Association®. Dr. Snyder oversees the Association's funding mechanisms; as the world's largest nonprofit funder of Alzheimer's research, the Association is currently investing \$310 million in more than 950 active best-of-field projects in 48 countries, including Australia. She is on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) and also serves on the study team for the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), a tool that will collect longitudinal diagnostic and therapeutic clinical data, including measures of cognition, function and safety, from individuals treated with FDA-approved Alzheimer's therapies in clinical settings nationwide. She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.

Johannes Streffer CMO AC Immune

Johannes Streffer is CMO of AC Immune and has previously led the development of a translational space in neuroscience at UCB. He was a member of the Alzheimer Disease Area Leadership Team at Janssen, Pharmaceuticals Inc. He has experience in early experimental trials and biomolecular modalities in Alzheimer's disease (AD) and has initiated a number of methodological and biomarker studies focusing on early diagnosis and translation. He was also the industrial lead for the European Medical Information Framework (EMIF)-AD, which in the Innovative Medicines Initiative (IMI)-EMIF program, fostered understanding of early biomarkers and change in the predementia AD spectrum. He is a member of the Scientific Advisory Board of the Alzforum. Johannes is a graduate of the University of Tübingen, Germany, where he received his medical degree. He also completed graduate studies on neuro-oncology and is Board certified in psychiatry and neurology. He has published more than 100 manuscripts and is a visiting Professor in the Department of Biomedical Sciences at the University of Antwerp.

Ivonne Suridjan Director Global Clinical Development & Neurology Indication Leader Roche

Ivonne Suridjan is an experienced clinical leader with 15 years of experience driving innovations and development of novel biomarkers and therapeutics in Psychiatry and Neurodegenerative disease. She is passionate about creating partnership and collaborating with people across functions and expertise to translate innovations from research concepts into routine clinical practice. She joined Roche 3 years ago and is leading the clinical development and disease area strategy for Neurology at Roche Diagnostics Ltd.

Charlotte Teunissen Professor of Clinical Chemistry Amsterdam University Medical Center

Charlotte Teunissen's drive is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, often by -omics methods, followed by biomarker assay development and analytical validation, and lastly, extensive clinical validation and implementation of novel biomarkers in clinical practice. She has extensive expertise with assay development on state of the art technologies, such as mass spectrometry and antibody-based arrays for biomarker discovery, ultrasensitive immunoassays, and in implementation of vitro diagnostic technologies for clinical routine lab analysis. She is responsible for the large well-characterised biobank of the Amsterdam Dementia cohort, containing >5200 paired CSF and serum samples of individuals visiting the memory clinical of the Alzheimer Center Amsterdam (a.o. controls, patients with Alzheimer, Frontotemporal, Lewy Bodies). To ensure the quality of the biosamples, the group studies pre-analytical effects, which are key to implementation. Charlotte is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers consortia. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers (10 academic centers + 10 non-academic centers), and the JPND bPRIDE project, that aims to develop targeted blood based biomarker panels for early differential diagnoses of specific dementias and is a collaborative project between 7 European and 1 Australian centers.

Arthur Toga Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences University of Southern California (USC)

Dr. Toga's research focus is on neurodegenerative disease and specifically works on Alzheimer's disease. He has pioneered some of the most widely used informatics systems in the world (e.g., IDA and GAAIN), supporting more than 150 multisite trials in AD and other neurological diseases and psychiatric disorders. His interdisciplinary work led to the creation of the Laboratory of Neuro Imaging (LONI), which he also directs and is one of the most advanced multidisciplinary neurological research centers. Funded by the National Institutes of Health (NIH), the Alzheimer's Association, the Michael J Fox Foundation among others, as well as industry partners, LONI houses one of the largest computing facilities and largest brain image repository in the world. He is an author or co-author of more than 950 peer-reviewed papers, 1100 abstracts and 80 book chapters or books, among them Brain Mapping: The Methods. He is the founding editor of the journal NeuroImage. Dr. Toga has received numerous awards for his research and teaching, including the Pioneer in Medicine Award, Smithsonian Award for Scientific Innovation and Giovanni DiChiro Award for Outstanding Scientific Research. He holds the Ghada Irani chair in Neuroscience and has been one of the world's top researchers on the AD Scientific Index, Top 200 Best Scientists in Neuroscience on Research.com, and listed as one of Thomson Reuters' and Clarivate Highly Cited Researchers for many years.

Andrew Trister Deputy Director, Health Artificial Intelligence Bill & Melinda Gates Foundation

Andrew Trister leads digital health and artificial intelligence at the Bill & Melinda Gates Foundation. His team invests in innovations that weave together artificial intelligence, mobile applications, objective sensor-based measurements, clinical care models and interoperable data infrastructure to improve care delivery at all levels of the health system. Andrew is a physician scientist passionate about leveraging technology to improve health care for all. He joined the foundation from Apple, where he led clinical research and machine learning for health features on the Apple watch and iPhone. Prior to Apple, he was the senior physician at Sage Bionetworks, where he designed and shipped ResearchKit, an open-source tool for large-scale clinical trials and developed infrastructure to share and collaborate on medical imaging. Andrew completed clinical residency in radiation oncology at the University of Washington, with additional focus areas in medical- and bio- informatics, earned an M.D., Ph.D. in bioengineering, MSE and BSE in computer science, and a B.A. in biological basis of behavior (neuroscience) all from the University of Pennsylvania.

Jetske van der Schaar PHD Researcher University of Amsterdam

I'm a PhD candidate at Alzheimer center Amsterdam, where I focus on medical ethical aspects in early stages of Alzheimer's Disease and other dementias. In addition, I'm an active advocate for patient and public involvement in research. I wrote a book about the personal impact of familial Alzheimer's Disease, which was published by Prometheus, I present a podcast on scientific progress for a broad audience, and I'm a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport.

Ernst van Koesveld Director General Longterm Care Government of Netherlands

Ernst van Koesveld (51) is Director-General Long-term Care at the Ministry of Health, Welfare and Sport, the Netherlands. His fields of responsibility include care and support for children and young people, the elderly and persons with disabilities as well as institutional, financial and labor market issues in the health care system. Before, he was director Health Insurance. The Dutch health system typically combines private responsibilities with public guarantees and rules. The major challenge for all stakeholders is to promote and achieve people-centered, integrated care ("the right care at the right place"). Prior to working for the Ministry of Health, Welfare and Sport, Ernst van Koesveld held various position at the Ministry of Finance, dealing with international decision-making (IMF and the World Bank), budgetary policy issues and structural reforms (social security, labor market, housing, pensions, taxation and decentralization, 2001-2014). He also worked for the UN Development Program in Lithuania and Vietnam, the Ministry of Economic Affairs and the Erasmus University Rotterdam. His educational background is in economics.

George Vradenburg Co-Chair Davos Alzheimer's Collaborative

George is the Chairman and Co-Founder of UsAgainstAlzheimer's (UsA2), a disruptive and catalytic force committed to stopping Alzheimer's by 2020. He serves as Co-Chair of the Davos Alzheimer's Collaborative, a coalition focused on driving global scientific, business, policy and financial coordination in Alzheimer's preparedness, co-convened in January 2020 by the Global CEO Initiative on Alzheimer's Disease (CEOi) and the World Economic Forum. In this role, George provides general oversight and advocacy and works to ensure the Collaborative remains sustainable and action-oriented. In 2011, the United States Secretary of the Department of Health and Human Services named George to serve on the National Alzheimer's Advisory Council on Research, Care and Services for the first-of-its-kind National Alzheimer's Strategic Plan. George received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. from Harvard Law School, cum laude.

Caleb Webber Director of Informatics and Data Science for the UK Dementia Research Institute Dementia Research Institute (DRI)

I am the Director of Informatics and Data Science for the UK Dementia Research Institute. After my PhD between the European Bioinformatics Institute and Cambridge University, I returned to Oxford to work on the first large-scale genome projects. I joined the UK-DRI in 2018 where I lead a team of informaticians and stem cell modellers working across a range of neurodegenerative disorders. I took up the post of Director of Informatics in 2022 with an initial focus on data integration and democratisation.

Stacie Weninger President Foundation for Biomedical Research and Innovation (FBRI)

Stacie Weninger is the President of FBRI and a Venture Partner at F-Prime Capital Partners. Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She is President of Alzforum; chairs the Collaboration for Alzheimer's Prevention; is Chairman of the Board for Rugen Therapeutics; is a member of the Board of Directors for Aratome, Atalanta, Eikonizo, Neumora, Sironax, and Target ALS; is a member of the External Advisory Board for Boston Children's Hospital's Rosamund Stone Zander Translational Neuroscience Center; is a member of the Scientific Advisory Boards for the Breuer Foundation, Brown University's Carney Center for Alzheimer's Disease Research, Denali Therapeutics, the Indian Institute of Science's Centre for Brain Research, the MIT Yang-Tan Center for Molecular Therapeutics, and the UK Dementia Research Institute. She served as a founding member of the Board of Directors for Denali Therapeutics.

Participants

Rufus Akinyemi Professor University of Ibadan College of Medicine
Emiliano Albanese Professor of Mental Health Università della Svizzera Italiana
Yahyah Aman Associate Editor Nature
Victor Amponsah Bediako Student University of Pecs Hungary
Cecilia Anza-Ramirez Researcher Cronicas
Houman Ashrafian Managing Partner SV Health Investors
Rhoda Au Professor Anatomy and Neurobiology Boston University
Felicity Baker Professor and Head of Music Therapy University of Melbourne
Gabriel Balmus Postdoctoral associate University of Cambridge
Sube Banerjee Professor of Dementia University of Plymouth
Payam Barnaghi Professor and Chair in Machine Intelligence Applied to Medicine Imperial College London
Nikki Bayliss Head of Development Alzheimer's Disease International (ADI)
Samantha Benham-Hermetz Director of Policy and Public Affairs Alzheimer's Research UK
Emily Berkowitz PR Alzheimer's Drug Discovery Foundation (ADDF)
Kate Bingham Managing Partner SV Health Investors
Martina Bocchetta Senior Research Fellow University College London (UCL)
Sacha Bozeat External Engagement Lead Roche
Janet Brownless Senior Director MSD
Rob Buckle Chief Scientific Officer Medical Research Council (MRC)
Chris Butler Clinical Senior Lecturer in Dementia Research Imperial College London
Phil Campbell Editor-in-Chief Nature
Dennis Chan Principal Research Fellow and Consultant Neurologist University College London (UCL)
Melissa Chan Atlantic Fellow, President Global Brain Health Institute (GBHI)
Clive Cookson Science Editor Financial Times (FT)
Francesca Cormack Chief Scientist Cambridge Cognition
Lucia Crivelli Neuropsychology Coordinator FLENI
Sebastian Crutch Professor of Neuropsychology, Dementia Research Centre University College London (UCL)
Rafael Calvo Professor Imperial College
Claudia Cooper Professor Queen Mary University London
Megan Cully Associate Deep Science Ventures
Lucy Cunningham Public Health Specialty Registrar University of Oxford
Nilton Custodio Neurologist
Marco Da Re Designer Imperial College London
Michael Devine Group Leader Francis Crick Institute
Isaac Ddumba Founder and CEO African Research Centre 4 Aging & Dementia (ARCD)A
Anna Dé Policy Adviser Women's Brain Project
Arno De Wilde Associate Life science Partners
Sarah Deeley Senior Clinical Country and Site Lead Biogen
Hilary Doxford PWD
Fiona Ducotterd CSO ARUK UCL Drug Discovery Institute
John Dwyer President Global Alzheimer's Platform
Chris Edgar Chief Scientific Officer Cogstate
Megan Eldred Senior Policy Advisor Office for Life Sciences
Hilary Evans Chief Executive Alzheimer's Research UK
Campbell Findlay Senior Consultant Hawthorn Advisors
Chris Fox Lead Dementia Portfolio Development Group University of Exeter
Jonathan Fox Public Affairs Manager Roche
Richard Gardner Senior Government Affairs & Policy Manager Janssen
Franca Gatto Director Division of Aging, Seniors and Dementia, Centre for Health Promotion Government of Canada
John Geddes Professor NIHR Oxford Health Biomedical Research Centre
Anne-Marie Glynn Deputy Chief Operations Officer Global Brain Health Institute (GBHI)

Claire Goodman Professor University of Hertfordshire
Sam Graham Senior Director and Head of External Affairs Biogen
Frank Gunn-Moore Professor of Molecular Neurobiology University of St Andrews
Peggy Hamburg Consultant National Academy of Medicine
Ashton Harper Head of Medical Affairs Roche Head of Medical Affairs for Roche Diagnostics UK & Ireland
Karen Harrison Dening Head of Research & Publications Dementia UK
Bert Hartog Senior Director Clinical Innovation Janssen
Amanda Heslegrave Senior Research Fellow UK Dementia Research Institute, University College London **Derek Hill** President Panoramic Digital Health
Juanita Hoe Professor of Dementia Care University of West London
Patrick Holford CEO Food for the Brain Foundation
Jacqueline Hoogendam Dementia Policy Coordinator Government of Netherlands
Kentaro Horibe Head of Cooperation System, Center for Comprehensive Care and Research on Memory Disorders
National Center for Geriatrics and Gerontology
Jeremy Hughes Consultant Better Communities
John Issac Senior Director Neuroscience Janssen
Adrian Ivinson National Director Dementia Research Institute (DRI)
David Jefferys Senior Vice President, Global Regulatory, Government Relations Eisai
Harry Johns President and CEO Retired
Bruce Jordan International Business Leader Roche
Sebastian Kohler Associate Professor Maastricht University
Julija Krupic Assistant Professor University of Cambridge
Anastasia Krywonos Doctor Oxford University Hospital
Ben Lacey Senior Fellow UK Biobank and University of Oxford
Louise Lafortune Senior Research Associate University of Cambridge
Giovanna Lalli Director of Scientific Affairs Dementia Research Institute (DRI)
Filipa Landeiro Senior Researcher in Health Economics University of Oxford
Lydia Lanman Senior Global Access Policy Lead Roche
Jaffar Latif Policy Adviser Dementia Office for Life Sciences
Jo Latimer Head of Neurosciences and Mental Health MRC
Roxanne Langlosie Senior Director Business Development IXICO
Nathalie Le Bastard Marketing Manager Fujirebio
Melanie Lee CEO LifeArc
Sen Liu Consultant Pason Pharmaceuticals
David Llewellyn Director and Professor University of Exeter
Simon Lovestone Global Lead Neuroscience Discovery and Translation Janssen
Miriam Lucar Research Assistant Universidad Peruana Cayetano Heredia Psychologist and Gerontologist
Jill Manthorpe Professor of Social Work Kings College London (KCL)
Olivia Marshall Public Affairs Manager Dementia Research Institute (DRI)
Tetsu Maruyama Chief Scientific Officer Alzheimer's Disease Data Initiative (ADDI)
Ayami Matsumura Section Chief for Dementia Care Ministry of Health, Labour and Welfare (MHLW)
Charlotte McIntyre Innovation Accelerator MHRA
Ruth McKernan Venture Partner SV Ventures
Jaime Miranda Professor of Global Health Universidad Peruana Cayetano Heredia
Susan Mitchell Head of Policy Alzheimer's Research UK
Hans Moebius CMO Athira
Rosa Montesinos Psychiatrist Instituto Peruano de Neurociencias
Lauren Moore Dementia Mission Policy Advisor Office for Life Sciences
Nula Moran Staff Writer BioWorld
Laura Nisenbaum Executive Director, Drug Development Alzheimer's Drug Discovery Foundation
Ryoji Noritake Director Health and Global Policy Institute (HGPI)
Richard Oakley Head of Research Alzheimer's Society
John O'Brien Professor of Old Age Psychiatry University of Cambridge Department of Health Lead

John O’Keefe Professor University College London

Russ Paulsen Chief Operating Officer UsAgainstAlzheimer’s

Jim Pearson Director of Policy and Research AlzScot

Robert Perneczky Head of the Alzheimer Treatment and Research Centre University of Munich

Micaela Pesantes Project Manager IMPACT

Timesh Pillay Imperial College London

Jo Pisani Trustee UK Dementia Research Institute

Richard Pither CEO Cytos

Enea Polotti Sr Director EMEA Strategic Marketing Eisai Europe Ltd

Shahmeen Rasul Junior Doctor in NHS

Annemie Ribbens VP Science icometrix

Alessandro Riccomben National Genomics Officer Microsoft UK

Jill Richardson Head UK Neuroscience, Executive Director MSD

Louise Robinson Professor of Primary Care and Ageing Newcastle University

Mark Roithmayr Chief Executive Officer Alzheimer’s Drug Discovery Foundation (ADDF)

Jane Rylett Scientific Director Institute of Aging (CIHR)

Takahiro Sakauchi Senior Associate Health and Global Policy Institute (HGPI)

Steve Salloway Martin M. Zucker Professor of Psychiatry and Human Behavior, Professor of Neurology Kent Hospital Rhode Island

Melanie Sanderson World Dementia Council

Vreni Schoenenberger Global Head of Public Affairs Novartis

Jonathan Schott Professor of Neurology at the Dementia Research Centre, UCL Institute of Neurology

Gustavo Sevlever Professor of Pathology FLENI

Samir Sinha Director of Geriatrics Mount Sinai Hospital

Louisa Stevenson Director of Public Affairs Lilly

Sudhir Sivakumaran Vice President, Neuroscience Program, Executive Director, CPAD & Interim Executive Director C-Path

John Skidmore CSO, ALBORADA Drug Discovery Institute University of Cambridge

Dirk Smeets CTO icometrix

Adam Smith Programme Director University College London (UCL)

Ian Smyth Director Mednet Group

Corinna Sorenson Professor & Director Duke University

Aimee Spector Professor of Old Age Clinical Psychology University College London (UCL)

Jina Swartz Chief Medical Officer Exciva; Academy of Medical Sciences

Emily Teller Director of Communications and Engagement UK Dementia Research Institute

David Thomas Head of Policy, Access and Innovation Alzheimer’s Research UK

Victoria Tischler Professor of Behavioural Science University of Surrey

Maria Tome Senior Scientific Officer European Medicines Agency

Dominic Trepel Assistant Professor (Health Economics) Trinity College Dublin

Mike Turner Principal Business Advisor SAS Institute

Silar Ultanir Group Leader Francis Crick Institute

Cornelia van Duijn Professor of Epidemiological Oxford University

Wim van Heck CEO icometrix

Peter Varnum Secretariat Davos Alzheimer’s Collaborative

Zoran Vasic Business Development and Regional Sales Director Fujirebio

Elisabetta Vaudano Principal Scientific Manager Innovative Health Initiative (IHI)

Everard (Jort) Vijverberg Neurologist Alzheimer Center

Myrra Vernooij-Dassen Professor emeritus Radboud University Medical Centre

Kousuke Wada Director for Dementia Strategy, Division of Dementia Policy and Community-Based Long-Term Care Promotion, Health and Welfare Bureau for the Elderly, MHLW Ministry of Health, Labour and Welfare (MHLW)

Wendy Weidner Research and Policy Project Lead Alzheimer’s Disease International (ADI)

Ben Williams Project Lead Care City

Julie Williams Professor Cardiff University

Rufus Akinyemi Professor University of Ibadan College of Medicine

Rufus Akinyemi is a neurophysician – scientist who uses the tools of genomics, epidemiology and implementation science to tackle vascular brain disorders and promote brain health, particularly in people of African ancestry. He is currently playing a leading role in the largest-ever study of stroke in Africa, the SIREN/SIBS Genomics Study funded by the NIH within the H3Africa Consortium. The study aims to unravel the genetic architecture of stroke in people of African ancestry and learn how these genes interplay with environmental factors. His FLAIR research is exploring the genetic basis of cognitive dysfunction after stroke. Findings from these studies will deepen our understanding of the mechanisms of vascular brain injury and inform how best to control vascular and other risk factors of stroke and VCID, including insights into new approaches to treatment. He also leads the IBADAN Brain Bank Project and the African Neurobiobank for Precision Stroke Medicine ELSI Study within the H3Africa Consortium and funded by the NIH National Human Genome Research Institute.

Emiliano Albanese Professor of Mental Health
Università della Svizzera Italiana

I am a physician and epidemiologist. In the past years I contributed to the spectacular growth of epidemiological evidence on dementia, and to the design and development of the WHO global public health response and action to dementia.

Yahyah Aman Associate Editor Nature

I am currently an Associate Editor at Nature Aging. I have obtained my PhD in Neuroscience from King's College London, where the focus of my research was on understanding the mechanisms of pain in Alzheimer's disease. During my postdoctoral work at University of Oslo and University College London, I investigated the molecular mechanisms of mitochondrial autophagy and protein homeostasis in human aging and age-related neurodegeneration, using a cross-species model system. At Nature Aging I am involved in handling and publishing research from across the entire spectrum of the aging field, ranging from the basic biology of aging to the impact of aging on society.

Victor Amponsah Bediako Student University of Pecs Hungary

My name is Victor Amponsah Bediako and I am Nursing at the University of Pecs with Faculty of Health Sciences. I was with Think and Plan Foundation and now doing a Nursing Programme at the University of Pecs, in Hungary. Cecilia Anza-Ramírez Research assistant CRONICAS - Universidad Peruana Cayetano Heredia. I am a biologist trained in Epidemiology at Universidad Peruana Cayetano Heredia (UPCH - Lima, Peru). Currently, I am part of the CRONICAS Center of Excellence in Chronic Diseases, also at UPCH. My research interests are focused on the occurrence and factors associated with cardiovascular and metabolic conditions, especially hypertension, diabetes, and obesity.

Cecilia Anza-Ramirez Researcher Cronicas

I am a biologist trained in Epidemiology at Universidad Peruana Cayetano Heredia (UPCH - Lima, Peru). Currently, I am part of the CRONICAS Center of Excellence in Chronic Diseases, also at UPCH. My research interests are focused on the occurrence and factors associated with cardiovascular and metabolic conditions, especially hypertension, diabetes, and obesity.

Houman Ashrafian Managing Partner SV Health Investors

Houman has 15 years clinical experience and a proven entrepreneur and company builder. He has been instrumental in founding eight SV backed companies where he is Managing Partner. Currently Visiting Professor and Head of Experimental Therapeutics at the University of Oxford and an Honorary Consultant Cardiologist, John Radcliffe Hospital, Oxford. Previously VP and head of the Clinical Science Group at UCB Pharmaceutical.

Rhoda Au Professor Anatomy and Neurobiology Boston University

Rhoda Au is Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine and Public. She also serves as Director of Neuropsychology at the Framingham Heart Study, where she is using technologies to develop digital cognitive biomarkers as surrogate indices of fluid and imaging biomarkers. She also seeks to facilitate development of a multi-sensory brain health monitoring platform that is customizable, flexibly responsive to the rapidly changing technology landscape, technology agnostic, and scalable. Further, she has a priority objective of transitioning from reliance on active engagement technologies to low/no engagement ones and developing methods for identifying and validating novel digital biomarkers. Her long-term objective is to enable solutions that move the primary focus of health technologies from precision medicine to a broader emphasis on precision brain health.

Felicity Baker Professor and Head of Music Therapy University of Melbourne

Professor Felicity Baker is a music therapy researcher, Director, International Research Partnerships for the Creative Arts and Music Therapy Research Unit at The University of Melbourne and has attracted AUS\$15.5M in competitive research funding. Felicity recently published the findings of a cluster RCT testing the effects of music interventions on depression in people living with dementia in residential aged care (n=318, The Lancet Healthy Longevity, 2022). She is International Project Leader of the recently completed HOMESIDE randomised controlled trial (n=432) which tests the effectiveness and cost-effectiveness of carer-directed home-based music interventions for people with dementia. Implemented in Australia, UK, Norway, Poland and Germany (EU JPND Scheme), the trial completed data collection in December 2022, with key results expected in April 2023. She is also principal investigator of MATCH (Music Attuned Technology Care eHealth). MATCH is an interdisciplinary project involving old age psychiatry, music therapy, neuropsychology, hardware and software engineering, and AI. It aims to develop and test a scalable technology for early detection and management of agitation. It uses sensor technology and AI to detect, measure, and categorise biobehavioural markers of agitation, and based on this continuous dataset, select, adapt, and attune music for physiological and emotional regulation.

Gabriel Balmus Postdoctoral Associate University of Cambridge

Dr. Gabriel Balmus is a group leader at UK Dementia Research Institute at University of Cambridge and a Lecturer in Medical Sciences at Trinity College. He was educated at the University of Iasi, Romania, graduating with a Doctor of Veterinary Medicine degree in 2007. He then carried out his PhD research with Prof Robert Weiss at Cornell University, USA on the role of chromosomal instability in cancer and development earning his PhD in Molecular and Integrative Physiology in 2013. Following his PhD, Gabriel performed his postdoctoral research with Prof Stephen Jackson at University of Cambridge, Gurdon Institute and the Wellcome Trust Sanger Institute where he developed an interest in the regulation of DNA damage responses in ageing and associated disorders towards identifying novel targeted therapies. In 2017 he moved to form his research group at UK Dementia Research Institute at University of Cambridge. The Balmus laboratory is interested in understanding how DNA lesions in the mature nervous system participate to ageing and neurodegenerative disease with particular emphasis on repeat expansion disorders such as Huntington's Disease. Interested in translational approaches aimed at bringing basic research concepts to the clinic, in 2017 Gabriel co-founded Adrestia Therapeutics Ltd with Stephen Jackson.

Sube Banerjee Professor of Dementia University of Plymouth

Sube Banerjee MBE, MBBS MSc MBA MD FRCPsych Executive Dean and Professor of Dementia in the Faculty of Health at the University of Plymouth. He trained at St Thomas's, The London School of Hygiene and Tropical Medicine, and the Institute of Psychiatry, King's College London. He served as the UK Department of Health's senior professional advisor on dementia leading the development of its National Dementia Strategy. His research focusses on quality of life and quality of care in dementia and the evaluation of new treatments and services. He works on health services, policy and strategies to improve health for older adults with complex needs and those with dementia; he practices as an old age psychiatrist. He has been awarded national and international awards for policy and research in dementia. Sube is a Trustee of Alzheimer's Society.

Payam Barnaghi Professor and Chair in Machine Intelligence Applied to Medicine Imperial College London Payam Barnaghi is Chair of Machine Intelligence Applied to Medicine in the Department of Brain Sciences at Imperial College London. He is a Co-PI in the Care Research and Technology Centre at the UK Dementia Research Institute (UK DRI CR&T). He leads the translational machine intelligence programme at the UK DRI CR&T.

Nikki Bayliss Head of Development Alzheimer's Disease International (ADI)

Nikki is responsible for leading ADI's fundraising, including managing relationships with key donors and partners. Nikki works closely with the rest of the team to support organisational development and achieve the objectives of ADI. Nikki has 20 years' experience of working in the voluntary sector, focusing on strategy development, fundraising, and capacity building. She has worked with a number of UK charities in the fields of international development, mental health, disability, welfare and heritage, including Sightsavers, Street Child, Prisoners Abroad, Scope and Samaritans. She holds a BA in English and Related Literature from the University of York and an MA in Cultural Theory from the University of Sussex.

Samantha Benham-Hermetz Director of Policy and Public Affairs Alzheimer's Research UK

Sam leads the policy and public affairs department at Alzheimer's Research UK, developing political strategy and wider influencing to ensure that research breakthroughs reach people affected by dementia. She is Chair of the Charity Medicines Access Coalition and sits on the Government's Dementia Programme Board.

Emily Berkowitz PR Alzheimer's Drug Discovery Foundation (ADDF)

Experienced and results-driven strategic communications and media professional with 10 years working for mission-driven nonprofit organizations. Currently serve as the Director of Public Relations at the Alzheimer's Drug Discovery Foundation (ADDF).

Kate Bingham Managing Partner SV Health Investors

Kate Bingham, Managing Partner at life sciences venture capital firm SV Health Investors.

Co-leads SV's biotech franchise which has a long history of building companies developing transformational new medicines. SV's investments have resulted in the launch of twenty drugs for inflammatory and autoimmune disease, blindness and cancer. In 2021 Kate was awarded a DBE in the Queen's Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purpose of finding and manufacturing COVID-19 vaccines. Kate is a board member of the Francis Crick Institute and helped launch the Dementia Discovery Fund. She has a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).

Martina Bocchetta Senior Research Fellow University College London (UCL)

Dr Martina Bocchetta is a Senior Research Fellow working at the Dementia Research Centre (University College London) and supported by a research fellowship awarded by the Alzheimer's Society. With a background in neuroanatomy and neuroimaging, her research currently focuses on the involvement of brain regions (especially subcortical structures) in the different forms of frontotemporal dementia, with the specific aim of defining in vivo imaging markers in the early stages of the genetic forms, in the context of the GENetic Frontotemporal Initiative (GENFI). Her PhD in Neuroscience (from the University of Brescia, Italy) was focused on the importance of the standardization of imaging biomarkers for their use in clinical settings and trials. She is a Fellow of the Advance Higher Education Academy in the UK and author of over 100 peer-reviewed publications.

Sacha Bozeat External Engagement Lead Roche

Sasha Bozeat is the Global External Engagement and Scientific Collaborations Lead for Alzheimer's disease at Roche. Sasha began her career working at the Memory and Cognitive Disorders Clinic in Cambridge, UK, where she developed a keen interest in cognitive testing together with a passion for helping to achieve a timely diagnosis for patients. Sasha completed her PhD at the MRC Cognition and Brain Sciences Unit, Cambridge where she was responsible for publishing some of the early observations on the structure of the semantic memory system. Janet Brownlees Senior Director of Neuroscience Biology Merck Senior Director at MSD Pharmaceutical working in drug discovery for neurodegenerative disease including dementia.

Janet Brownless Senior Director MSD

Senior Director at MSD Pharmaceutical working in drug discovery for neurodegenerative disease including dementia.

Rob Buckle Chief Scientific Officer Medical Research Council (MRC)

Dr Rob Buckle is Chief Science Officer at the Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI) and the main Government agency responsible for UK biomedical research. MRC invests ~£800m each year on world-class research across the biomedical spectrum. As CSO, Rob oversees MRC's scientific operations and funding procedures, major science initiatives and strategic funding partnerships. In relation to dementias research, Rob has been a major contributor to the development of the UK Government's strategic approach to this area and provided oversight for the establishment of the UK Dementia Research Institute and the MRC Dementias Platform UK. Internationally, Rob has served as a founder member on the Executive Boards for both the EU's Joint Programming Initiative in Neurodegeneration (JPND) and the Centres of Excellence in Neurodegeneration (COEN) initiative, and chaired the OECD working group on big data in dementia research between 2014/15.

Chris Butler Clinical Senior Lecturer in Dementia Research Imperial College London

I am an academic cognitive neurologist with extensive research and clinical experience in cognitive disorders. My research interests lie in global health, cognitive testing and neuroimaging of dementia. I am also engaged in clinical practice at the Imperial Memory Service at Charing Cross Hospital, London. Rafael Calvo Professor Imperial College London Professor at the Dyson School of Design Engineering, Imperial College London, and its Director of Research. He is director of the Wellbeing Technology Lab that focuses on the design of systems that support wellbeing in areas of mental health, medicine, and education. He has developed health technologies to support people with dementia, asthma, insomnia, mental illness and diabetes.

Rafael Calvo Professor Imperial College

Professor at the Dyson School of Design Engineering, Imperial College London, and its Director of Research. He is director of the Wellbeing Technology Lab that focuses on the design of systems that support wellbeing in areas of mental health, medicine, and education. He has developed health technologies to support people with dementia, asthma, insomnia, mental illness and diabetes.

Phil Campbell Editor-in-Chief, Nature

Sir Philip Campbell is Editor-in-Chief of Springer Nature, publishers of the Nature portfolio, Springer journals and books, Scientific American and other books, journals and magazines. Originally a physicist, he was Editor-in-Chief of Nature 1995-2018. He was a founding trustee and also Chair of the research funding charity MQ.

Dennis Chan Principal Research Fellow and Consultant Neurologist University College London (UCL)

Dr Dennis Chan is Principal Research Fellow at the Institute of Cognitive Neuroscience, University College London having moved to UCL from the University of Cambridge in 2020. He is a practising neurologist, running memory clinics in South East England, and as well as his medical qualification he holds dual research doctorates in basic and clinical neuroscience, having completed his initial PhD with Nobel Laureate John O'Keefe at UCL. His primary clinical and academic interest is the detection of early Alzheimer's disease using novel tasks based on hippocampal neuroscience and he has pioneered the use of various tech-based methodologies for AD diagnosis including VR- and app-based tests. In collaboration with Professor O'Keefe he is investigating the effects of AD pathological spread in mouse models of AD, translating outputs from the animal work to the study of at-risk human cohorts. Dr Chan co-leads the digital hub within the Alzheimer's Research UK Initiative on Early Detection of Neurodegenerative Diseases (EDoN). His work has been published in Nature and The Lancet, among other journals, and he is funded by Alzheimer's Research UK and the Wellcome Trust.

Melissa Chan Atlantic Fellow, President Global Brain Health Institute (GBHI), World Young Leaders in Dementia (WYLD)

Melissa Chan works with tri-sector partners (business, government and nonprofit) in health and social care to lead service design, innovation, and growth projects. She is currently with the University of Luxembourg, working on co-creating a toolkit with companies that implements innovative measures to improve brain health at the workplace. Melissa has a keen interest in brain health, ageing, dementia, and carer support - particularly in the intersection of research and translation into practice and in bringing evidence-based interventions to diverse populations. She has led multiple initiatives related to care and support delivery for dementia, including CARA by Dementia Singapore, a national platform to facilitate the safe return of people living with dementia. She is a Senior Atlantic Fellow with the Global Brain Health Institute (GBHI), Trinity College Dublin, and President of the World Young Leaders in Dementia (WYLD) Network, driving dementia innovation across disciplines and borders.

Clive Cookson Science Editor Financial Times (FT)

Clive Cookson has been science editor of the Financial Years for 30 years. He takes a keen interest in research and policy relating to dementia and Alzheimer's disease.

Claudia Cooper Professor Queen Mary University London

I am centre lead and professor of Psychological Medicine at Wolfson Institute of Population Health, Queen Mary University of London.

Francesca Cormack Chief Scientist Cambridge Cognition

Francesca is Chief Scientist at Cambridge Cognition. She has extensive experience of statistics, cognitive neuroscience and cognitive test development in a range of clinical populations. Since joining Cambridge Cognition in 2014, Francesca has worked to develop novel cognitive testing methodology to support high-frequency, near patient testing using digital technology, providing researchers and healthcare providers with unique insights into cognitive health. Francesca obtained a PhD in Dementia with Lewy Bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.

Lucia Crivelli Neuropsychology Coordinator FLENI

Dr. Crivelli is the Head of Neuropsychology at FLENI, Buenos Aires, Argentina, where she leads a team of twenty researchers and clinicians. She is also an Associate Professor of Neuropsychology at Maimonides University and a Research Scientist at CONICET (National Institute for Scientifically and Technological Research) in Argentina. Her research interests include the early detection and prevention of cognitive decline and dementia in developing countries. By applying her efforts to the prevention of dementia across Latin America, her work has focused on LatAm FINGERS, the first multi-domain lifestyle intervention in the region. Her role as Principal Investigator has been crucial for designing the project and the congregation of the most prestigious centers and leaders from Latin America. In addition, during the last two years, she has studied the cognitive consequences of COVID-19 and the psychological effects of social isolation. She has published work on these topics in leading peer-reviewed medical journals. Finally, the pandemic has also drawn her work to tele-neuropsychology, where she published the first recommendations for Latin America.

Sebastian Crutch Professor of Neuropsychology, Dementia Research Centre University College London (UCL)

Sebastian Crutch is Professor of Neuropsychology at the Dementia Research Centre, UCL Institute of Neurology. His research focuses on rare and young onset dementias, exploring topics including dementia-related visual impairment. He directed the Created Out of Mind 2016-2018 dementia and arts residency at The Hub, Wellcome Collection, which aimed to shape and enrich public and professional perceptions through collaborations between artists, scientists and people living with dementia. He currently co-leads Rare Dementia Support (<http://www.raredementiasupport.org/>) which exists to provide care, support and advice to people living with rarer dementias, and leads a 5-year ESRC-NIHR research programme evaluating the impact of support groups that mix peer and professional experience.

Megan Cully Associate Deep Science Ventures

Megan Cully is an associate at Deep Science Ventures, a venture builder in London, UK. Megan developed her hands-on expertise in cell biology, biochemistry, in vivo models and cancer biology during her PhD at the University of Toronto and post-doctoral work at Cancer Research UK's London Research Institute (now part of the Crick). She then spent nearly 10 years as an editor and news writer on various Nature journals, mainly Nature Reviews Drug Discovery, where she covered topics including drug delivery, gene therapy, screening strategies, neurobiology and infectious diseases. At DSV, Megan helps build companies that could have curative potential in diverse areas including cell and gene therapies and neurodegeneration.

Lucy Cunningham Public Health Specialty Registrar University of Oxford

Lucy Cunningham, MFPH: I am a Public Health Specialty Registrar training in the Thames Valley region. I am currently working at the Nuffield Department of Population Health (NDPH), University of Oxford, in the Health Economics Research Centre (HERC). I am involved in the HEPAD pilot study – Health Economics of Pre-dementia Alzheimer's Disease. HEPAD is a national health economics study which aims to understand better the economic impact of early stages of Alzheimer's Disease. I have worked in public health research and health improvement in both the UK and the US. My experience and educational background focus on public health research in relation to diet, physical activity, and the management of preventable chronic diseases within populations facing health inequalities. I am keen to gain a wide experience of public health during my training in Thames Valley.

Belen Custodio Health Administrator

I am a health administrator who believes that health promotion and prevention can greatly impact the health of all people. I also believe that promoting brain health can lead to better overall health, because by protecting our brains we protect many more organs and take care of our health.

Nilton Custodio Neurologist

A neurologist, master in medicine and neuroscience, PhD in neuroscience, investigator in dementia (Alzheimer disease and related dementia), with particular interest in brief cognitive tests for the detection of cognitive impairment and dementia adapted for individuals with low educational level. The aim of our group research is to provide high standards for brief cognitive tests to detect dementia in urban and rural illiterate populations; as well as in indigenous populations (quechua and aymara). I carried out the first dementia prevalence study in Peru, and validated the brief cognitive tests for dementia screening in individuals with a high educational level: The clock-drawing test (CDT), Addenbrooke's Cognitive Examination (ACE), memory alteration test (M@T), and the INECO frontal screening. Since 2013 I have served as the head of the Peruvian Institute of Neurosciences. Since 2011, I have been advisor for more than 20 master degrees in medicine and epidemiology. I have established national collaboration agreements with the National Institute of Neurological Sciences (study of apolipoprotein in controls and patients with Alzheimer's disease) and the National Institute of Neoplastic Diseases (longitudinal study of cognitive impairment in women with breast cancer undergoing chemotherapy).

Marco Da Re Designer Imperial College London

My projects of the last two years aim to tackle wicked problems, focusing on supporting human motivation and well-being in contexts of crisis. I am a design strategist and researcher. My goal is to ensure that design is purposeful, practical, effective and improves the well-being of society by designing meaning. Recently my interest has focused on design in times of crisis. The last project is called Alta Quanto, set in the city of Venice. It is a new way of preparing for and warning about unexpected and exceptional flooding.

Isaac Ddumba Founder and CEO African Research Centre 4 Aging & Dementia (ARCD)

Am a founder and Executive director of African Research Center 4 Ageing & Dementia. As well as a senior lecturer at Victoria University in Uganda. Currently, am a PhD student at University of Maastricht. Have a strong bias in Dementia and Ageing research in Sub-Saharan Africa.

Anna Dé Policy Adviser Women's Brain Project

Anna Dé leads the policy chapter of the Women's Brain Project (WBP). She acts as the policy advisor to the WBP, advising on global and European policy matters. Anna is a Global / European Public Affairs professional, with 22 years' international consultancy experience. She is specialised in International Healthcare Public Affairs: supporting clients with multinational policy-led healthcare communications and strategies, and how to best engage on healthcare policy matters at international, EU and national levels.

Arno De Wilde Associate Life Science Partners

Current role: life sciences investor with a passion for neuroscience. Director and co-founding member of the Dementia Fund at EQT Life Sciences.

Sarah Deeley Senior Clinical Country and Site Lead Biogen

Experienced clinical research professional supporting the country strategy for neurodegenerative diseases at Biogen.

Michael Devine Group Leader Francis Crick Institute

I am a neurologist and a researcher studying the interaction between mitochondria and synaptic function in health and in neurological disease.

Hilary Doxford

I was diagnosed with early onset dementia in 2012. I am an Ambassador for the Alzheimer's Society and a member of their Research Network. I am a former member of the World Dementia Council and was also Vice-Chair of the European Working Group of People with Dementia which inspired me to co-found the 3 Nations Dementia Working Group (3NDWG). I am passionate about improving the quality of life for those affected by dementia. I want to work with and help those who are trying to help me and my friends whilst I still can.

Fiona Ducotterd CSO ARUK UCL Drug Discovery Institute

As Chief Scientific Officer of the Alzheimer's Research UK Drug Discovery Institute at UCL in London, Professor Ducotterd leads a team of multidisciplinary scientists and a portfolio of preclinical projects to make new medicines for neurodegenerative diseases. Professor Ducotterd is an experienced global leader (UK, USA, Japan, China) and an expert in neuroscience drug development and different therapeutic modalities as well as strategic alliance and business development with companies including; Merck, GSK, Vertex and Eisai.

John Dwyer President Global Alzheimer's Platform

John R. Dwyer, Jr. is the President of the Global Alzheimer's Platform Foundation (GAP). GAP is a patient centric non-profit organization dedicated to the mission of reducing the time and cost of AD trials while improving the quality and diversity of AD and other CNS therapeutic clinical studies. Over the last 4 years, in collaboration with our network of many of the leading private and public CNS clinical trial sites in North America, GAP-Net, GAP has or is conducting over a dozen Phase 2 or 3 therapeutic studies in AD or PD. These "GAP-enabled" trials have consistently recruited and enrolled 30-50% faster than the industry averages. In the last two years, GAP has also become a leader in the biomarker and data analytics field with its launching of Bio-Hermes, the largest comparison study of many of the leading blood plasma and digital cognitive tests relative to Beta-Amyloid PET in the AD field today (n=1,000). It is also the most diverse with over 22% of the participants coming from traditionally underrepresented communities. GAP recently announced the launch of its second biomarker study, Aphelia (n~1,000) which will be transatlantic, as well as 5 GAP-enabled trials focusing on enhanced participation of underrepresented populations in these trials. All of GAP's data and inventory of samples will be the subject of a multi-modal analytical effort including AI/machine learning based in silico modeling to improve clinical trial design and new target development. Prior to GAP, John served as the co-founder and Chairman of Telcare, Inc. (Phillips Medizine), a high technology manufacturer of the first wirelessly enabled blood glucose meter system empowering patients with diabetes to better manage their disease. Mr. Dwyer first became a CEO at the age of 30. In the following years, he has held "C" level positions in six emerging growth companies in the healthcare industry. His past assignments have included serving as CEO of e-Medex, Inc., which merged with Active Health Management (Aetna) to become the leading provider of population health management services. He was also a co-founder and Chairman of CodeRyte, Inc., a venture-backed seller of medical billing software using AI/natural language processing to generate billing codes. CodeRyte was purchased by 3M in 2012. Mr. Dwyer co-founded Us Against Alzheimer's and serves on their Board. UsA2 is a patient advocacy group focused on changing the way the country addresses the threat posed by Alzheimer's. He also co-founded the first political action committee focused on a specific disease, the Alzheimer's Action PAC. Mr. Dwyer is frequently interviewed on regulatory and patient related issues in the Alzheimer's and CNS space more broadly. He also regularly speaks on health information issues and the business risks associated with the regulatory and payer process. Mr. Dwyer is a graduate of Marquette University and the Cornell Law School.

Chris Edgar Chief Scientific Officer Cogstate

Dr. Chris Edgar has an extensive background in drug development and clinical trials methodology and is an expert in the development, validation and application of clinical outcome assessments (COAs). Dr. Edgar has held positions as scientific director at Cognitive Drug Research, senior clinical lead at Bracket/UBC, principal scientist at Roche, and is currently Chief Science Officer at Cogstate. Dr. Edgar has worked across all phases of clinical development and in multiple therapy areas, specializing in neuroscience, cognition and performance-based outcome assessments.

Megan Eldred Senior Policy Advisor Office for Life Sciences

Megan works in the UK's Office for Life Sciences, leading the development of the UK Government's recently announced Dementia Mission. This is one of the eight healthcare missions being tackled through the UK's Life Sciences Vision and Drugs Strategy, in collaboration with industry, academia, the third sector and the NHS. The Mission aims to improve translational capabilities in dementia and neurodegeneration by developing precision medicine tools that will help speed up clinical trials while improving accuracy and chance of success. Situated within a rich UK research ecosystem, the mission will build on existing UK and global dementia research initiatives and clinical research infrastructure. Megan has a PhD in Physiology, Development and Neuroscience, investigating the cellular and molecular mechanisms of neuronal patterning during brain development.

Hilary Evans Chief Executive Alzheimer's Research UK

Hilary Evans is Chief Executive of Alzheimer's Research UK (ARUK), the UK's leading dementia research charity. ARUK is committed to investigating the causes of dementia and developing ways to prevent, diagnose, treat and, ultimately, cure all forms of the condition. As Chief Executive since 2015, Hilary has led the transformation of the charity to one of the leading medical research charities in the UK. She has overseen a significant growth in income in recent years, with ARUK being one of the fastest growing UK charities. This growth has significantly enhanced the organisation's ability to fund new innovative projects, particularly those that unite charity, academic and private sectors in the search for new dementia treatments. Hilary is driven and fascinated by ideas that can make a difference and has led major public campaigns to change public perceptions of dementia and break down the stigma around these diseases. Before joining Alzheimer's Research UK Hilary worked at Age UK, improving the lives of people in later life both in the UK and internationally. She also brings experience of working in Government and with the pharmaceutical industry. Hilary is a Trustee of the Association of Medical Research Charities, a member of the World Dementia Council and holds an honorary doctorate in medicine from The University of Exeter.

Campbell Findlay Senior Consultant Hawthorn Advisors
I will be there in the capacity to assist Laurence Geller.

Chris Fox Lead Dementia Portfolio Development Group
University of Exeter

Professor Fox spent 6 years training in psychiatry, researching trauma/personality assessments, treatment and psychometric assessment development with the Ministry of Defence.

Jonathan Fox Public Affairs Manager Roche

Jonathan is highly experienced within the life sciences sector, with in-depth knowledge of market access, public affairs and the healthcare policy environment across the UK and Ireland. He has a strong track record of developing long-term strategic partnerships with NHS leaders, patient charities, professional groups and other key partners across the healthcare ecosystem. Jonathan is passionate about improving the lives of patients through the adoption and spread of innovation across the NHS.

Richard Gardner Senior Government Affairs & Policy Manager Janssen

Richard Gardner leads Government Affairs and Policy work for neuroscience at Janssen in the UK. He has extensive experience in healthcare government affairs and policy from consulting and the charity sector.

Franca Gatto Director, Division of Aging, Seniors and Dementia, Centre for Health Promotion Government of Canada

Franca Gatto Franca Gatto is the Director of the Aging, Seniors and Dementia in the Centre for Health Promotion at the Public Health Agency of Canada, a position she has held since September 2017. Franca works with stakeholder organizations and provincial and territorial governments across Canada, and is the federal government focal point for health issues affecting Canada's older adult population. Through federal investments, partnerships and policy leadership, the Division of Aging, Seniors and Dementia seeks to promote healthy aging in the areas of dementia, injury prevention, and mental health. Franca and her team is responsible for the development of Canada's first national dementia strategy, A Dementia Strategy for Canada: Together We Aspire, launched in 2019. Along with her team she is spearheading the implementation of the national dementia strategy and is administering federal investments of over \$100M which support key components of the strategy. Prior to joining the Public Health Agency, Franca gained over 25 years of experience in providing strategic policy and communications advice to decision-makers in the federal Health Portfolio, primarily at Health Canada. Franca holds a Master of Business Administration from the University of Ottawa and a Bachelor of Public Relations from Mount Saint Vincent University in Halifax, Nova Scotia. Franca also completed a Masters Certificate in Public Sector Leadership from Carleton University/Sprott School of Business.

John Geddes Professor NIHR Oxford Health Biomedical Research Centre

John Geddes is Director of the NIHR Oxford Health Biomedical Research Centre.

Anne-Marie Glynn Deputy Chief Operations Officer
Global Brain Health Institute (GBHI)

Anne-Marie Glynn is responsible for Operations at the Global Brain Health Institute (GBHI), Trinity College Dublin, home to the Atlantic Fellows for Equity in Brain Health.

Claire Goodman Professor University of Hertfordshire
Claire is Professor of Health Care Research at the Centre for Research in Public health and Community Care (CRIPACC) University of Hertfordshire. Fellow of the Queen's Nursing Institute and a National Institute of Health Research (NIHR) Senior Investigator. She is a member of Alzheimer's Society Research Strategy Committee. Her research focuses on older people including those affected by dementia, with health and social care needs living at home or in long term care settings. She led the national evaluation of Dementia Friendly Communities (DEMCOM) and currently leads the NIHR DACHA study (Developing research resources And minimum data set for Care Homes' Adoption and use) <https://dachastudy.com/>

Sam Graham Senior Director and Head of External Affairs Biogen

Head of External Affairs, Biogen UK and Ireland.

Frank Gunn-Moore Professor of Molecular Neurobiology University of St Andrews

I am a molecular neurobiologist who studies the development and survival of mammalian neurons. My approach to achieve this has been to combine all three science disciplines, publishing in biological, chemical and physics-based journals. We have made discoveries in understanding the early stages of Alzheimer's disease, pioneering new models and identified potential therapeutic targets. In addition, we have developed novel optical technology that allows the manipulation and imaging of cells including the airy-beam light sheet microscope. At the University of St Andrews, I am the Head of the School of Biology (400 staff, 700 students). Externally, I am Deputy Director of the Scottish Universities Life Sciences Alliance which previously helped to develop the European Lead Factory and the National Phenotypic Screening Centre. I have sat on many different funding agencies. More recently, I have led the Fundamental Sciences in the Scottish Dementia Research Consortium, and sit on the Scottish Government Cross Party committee in the Life Sciences.

Peggy Hamburg Consultant National Academy of Medicine

Dr. Hamburg is an internationally recognized leader in public health, medicine, and science, perhaps best known for her expertise on biological threats and biomedical research and innovation. She currently serves as co-President of the InterAcademy Partnership (IAP), an international consortium of national academies of science and medicine working to advance the role of science in evidence-based policy decisions. Previously, Dr. Hamburg has served in numerous leadership roles including: Commissioner of the Food and Drug Administration; National Academy of Medicine Foreign Secretary, President/Chair, American Association for the Advancement of Science, Vice President/Senior Scientist, Nuclear Threat Initiative; Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services; New York City Health Commissioner; and Assistant Director, National Institute of Allergy and Infectious Disease. Dr. Hamburg sits on a range of boards and advisory committees, including Alnylam Pharmaceuticals, The Nuclear Threat Initiative, The Council on Foreign Relations, The Commonwealth Fund, The Urban Institute, The Nature Conservancy, The Lasker Foundation, Ending Pandemics and Resolve to Save Lives. Dr. Hamburg is widely published and has received numerous awards and honorary degrees. She is a graduate of Harvard College and Harvard Medical School and is board-certified in Internal Medicine.

Ashton Harper Head of Medical Affairs Roche Head of Medical Affairs for Roche Diagnostics UK & Ireland

He leads a team responsible for clinical research across oncology, cardiology, neurology, infectious diseases, critical care and women's health. MBBS and a B.Sc. in physiology and pharmacology from University College London. Trained as a gastrointestinal surgeon in the NHS achieving membership of the Royal College of Surgeons. During his career he has initiated numerous interventional clinical trials in a range of therapeutic areas and has lectured across the globe. Published in the fields of surgery, gastroenterology, neurology, infectious diseases and microbiology.

Karen Harrison Dening Head of Research & Publications Dementia UK

KHD is a nurse by background with three nursing registrations (RMN, RNMH & RN) with over 45 years nursing experience, most spent in dementia care in a various settings. KHDs last clinical role was that of Consultant Admiral Nurse in three North London Boroughs. KHD joined Dementia UK in 2008 and a part-time PhD at University College London focusing on advance care planning in the context of palliative and end-of-life care in dementia in the Division of Psychiatry in the Faculty of Brain Sciences. Upon successful completion KHD became the Head of Research and Publications at Dementia UK (part-time). More recently KHD took up a part-time Professorial role in Dementia Nursing at De Montfort University, Leicester. As well as my academic interests, KHD has influenced policy and guidance in the field of dementia, such as, the National Institute for Health and Care Excellence (NICE) dementia guideline refresh. KHD is involved in several large research studies, both nationally and internationally; for example, PriDem, CareCoach. Research interests include; dementia care, case management, care coordination, palliative and end-of-life care and advance care planning, collaborative networks.

Bert Hartog Senior Director Clinical Innovation Janssen

Bert is an experienced Senior Director and Innovation Leader. He leads transformational innovation projects that have the goal to shape the future of clinical trial design and execution, improve the clinical trial experience and position Janssen as a role model in patient-centered clinical research. Bert is an international industry expert in Clinical Research and Digital Health. He graduated in Biomedicine and obtained a PhD in Medicine from Utrecht University in the Netherlands. He held roles in Clinical Operations-, QA- and IT-management before joining Janssen's Clinical Innovation team in 2015. His main focus today is developing capabilities for digital health solutions in clinical trials, including harmonization of digital outcome measures and technologies for patient engagement and remote monitoring. In 2019 Bert co-founded the DEEP initiative to co-create a novel integrated ecosystem for the development, validation and acceptance of digital measures. Bert continues to support DEEP, which is now an independent company.

Amanda Heslegrave Senior Research Fellow UK Dementia Research Institute, University College London

I have worked at UCL for the past 10 years on fluid biomarkers for neurodegenerative diseases and work closely with Prof Henrik Zetterberg. I manage and run the fluid biomarker laboratory and the Biomarker Factory where we collaborate to push forward all aspects of biomarker research.

Derek Hill President Panoramic Digital Health

Professor Hill holds a Chair of Digital Health at University College London and is CEO of Panoramic Digital Health, a company developing a wearable sensor platform, and collaborating with large and small life-science businesses to support their commercial, technical and regulatory strategy. He was previously CEO of IXICO, which he co-founded in 2004 and grew the business as a provider of regulatory compliant image data management and analysis solutions to the pharmaceutical industry. Derek has spent most of his career involved in clinical trials for neurodegenerative diseases, including working on novel drug development tools and engaging with regulators to advance their maturity.

Juanita Hoe Professor of Dementia Care University of West London

Juanita Hoe is Professor of Dementia Care at University of West London. She is a mental health nurse by background and clinically her nursing career focused on older person's mental health care, and she has worked within inpatient, day hospital, community and acute hospital settings. Juanita has also worked as an Admiral Nurse (dementia nurse specialist) supporting people with dementia and their families. Her research experience builds upon her clinical expertise and focuses on building an evidence-base to improve health services and disseminating this knowledge into practice to deliver high quality patient care. This includes co-designing psychosocial interventions with service users and family carers for crisis management, needs assessment, peer support, reducing agitation, facilitating early diagnosis in dementia and strategies to support family carers. Juanita is also the lead for postgraduate education at the Geller Institute of Ageing and Memory and is involved in the teaching and supervision of postgraduate and doctoral students.

Patrick Holford CEO Food for the Brain Foundation

I head the Alzheimer's is Preventable project at the charitable Food for the Brain Foundation testing, online and free, over 400,000 people's Cognitive function, Dementia Risk Index and working to positive change diet and lifestyle behaviours to reduce risk. See foodforthebrain.org

Jacqueline Hoogendam Dementia Policy Coordinator Government of Netherlands

Jacqueline Hoogendam started her professional career as a lawyer in the private sector. In 1994 she switched to the Dutch government, the Ministry of Justice, with specific tasks on crime prevention and business ethics. In 2007, she was offered a position at the Ministry of Health, Welfare and Sport. At the Department of Long-term Care she became responsible for the policy on dementia. Currently, Jacqueline is co-ordinator of international dementia policy and of dementia research, both on a national and international level. She also acts as co-ordinator of international affairs in long-term care. As part of this position, Jacqueline represents The Netherlands' government in the both Management Board and the Executive Board, as vice-chair, of the EU Joint Programme Neurodegenerative Disease Research (JPND), in the World Dementia Council, in the European Group of Governmental Experts on Dementia, in the UNECE Standing Working Group on Ageing and in the General Assembly of the Active and Assisted Living Research and Development Programme (AAL).

Kentaro Horibe Head of Cooperation System, Center for Comprehensive Care and Research on Memory Disorders National Center for Geriatrics and Gerontology

Dr. Kentaro "Ken" Horibe is a neurologist at the National Center for Geriatrics and Gerontology (NCGG), Japan. He is currently the Head of Cooperation System Management at the Center for Comprehensive Care and Research on Memory Disorders. From 2010 to 2012, Dr. Horibe served as a Senior Specialist for Dementia in the Ministry of Health, Labour and Welfare. He was involved in formulating "the Five-year Plan for Promotion of Measures against Dementia (Orange Plan)". Dr. Horibe was one of the founding member staff of the Agency for Medical Research and Development (AMED), which was modeled after the U.S. National Institute of Health (NIH) in 2015 and contributed to the launch of the ORANGE registry, the first nationwide dementia registry in Japan.

Jeremy Hughes Consultant Better Communities

Jeremy Hughes CBE was Chief Executive of Alzheimer's Society UK throughout the 2010s. He led the Dementia Friends programme with 4 million joining in the UK and programmes being set up worldwide. He was a member and vice-chair of the World Dementia Council and is co-char of the UK Prime Minister's Champion Group for Dementia Friendly Communities. Jeremy now works as a consultant with a range of public, private and voluntary sector organisations.

John Issac Senior Director Neuroscience Janssen

John joined Johnson & Johnson in September 2016. In this role John uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer's Disease and Mood Disorders. Prior to joining Johnson & Johnson, since November 2014, John was Head of Neuroscience and Mental Health at the Wellcome Trust. Previous to that he worked at Eli Lilly and Company at their neuroscience research campus near London, UK. At Lilly he led a team of labs dedicated to identifying new therapies for Alzheimer's disease and schizophrenia. John's scientific interests centre on synaptic mechanisms in circuit function, and how dysfunction causes psychiatric and neurological disease. John obtained a BSc in Pharmacology and Biochemistry at the University of Southampton in 1990 and remained at Southampton for his graduate work, studying mechanisms of epilepsy with Prof Howard Wheal. He then completed postdocs at UCSF with Rob Malenka and Roger Nicoll, and then in Bristol with Graham Collingridge before before establishing his own lab there. He rose up through the ranks to full Professor and left in 2004 to set up a lab at the Intramural Program at NINDS/NIH in Bethesda, MD, USA.

Adrian Ivinson National Director Dementia Research Institute (DRI)

After PhD training in genetics Adrian joined the Nature Publishing Group, including terms as Editor of Nature Medicine and Publisher of the Nature monthly journals. He joined Harvard Medical School in 2001 as the founding Director of the Harvard NeuroDiscovery Center and later Brigham and Women's Hospital as Executive Director of the Ann Romney Center for Neurologic Diseases and the Evergrande Center for Immunologic Diseases. He returned to the UK to join the nascent UK Dementia Research Institute in 2017 as co-director and COO where he is responsible for establishing and managing all operational aspects of this major new national institute. Throughout his biomedical career Adrian has advocated for more collaborative approaches to tackling the most challenging neurological diseases and has been directly involved in designing and running a series of successful multi-institutional research programmes involving academia, industry, foundations and governmental agencies. He still publishes every now and again, mostly on neurogenetics, biomedical research capacity building and collaboration.

David Jefferys Senior Vice President, Global Regulatory, Government Relations Eisai

Previous position/Career highlight: Physician and Cardiologist, 21 years Senior Registrar, Agency CEO, CPMP/CHMP member. President of TOPRA. Professor of Medicine.

Harry Johns President and CEO Retired

Harry Johns is the immediate past CEO of the Alzheimer's Association, serving in that role from 2005 through 2022. He is now a volunteer for the Association and the Alzheimer's Impact Movement. He also serves as a member of the board of ALZpath, an organization dedicated to transforming the Alzheimer's disease ecosystem. He was with the American Cancer Society for more than twenty years, ending his career there as EVP for Strategy and as a member of the four person executive team. He has served on the board of the National Health Council and as a member of the board and executive committee of Research America. Harry was appointed by the US Secretary of Health and Human Services and served for six years as a member of the Advisory Council on Alzheimer's Research, Care, and Services. He was appointed by the UK Secretary of State for Health and Social Care, on behalf of the G8, as a member of the World Dementia Council after its creation in 2014. He served as Chair of the Council and its trustees from 2018-2021 and serves today as a member of the Council and as a trustee.

Bruce Jordan International Business Leader Roche

Bruce Jordan is the International Business Leader for Personalised Healthcare Solutions - Neurology and General Medicine - at Roche Diagnostics since 2013. Bruce originally joined Roche Pharmaceuticals in Basel in 2005 with the Herceptin program to support the worldwide adoption of Her2 testing. Bruce moved to Roche Diagnostics in 2008 and initiated the Alzheimer's Disease developments, expanding this to cover CSF and plasma tests for broader neurological disorders, including the NeuroToolkit collaborative. Bruce qualified as a Medical Laboratory Scientist at Southampton General Hospital in 1995 and also worked at the Royal Marsden Hospital specialising in Haematology and Transfusion Medicine. Bruce has a Ph.D in cancer research from the University of Würzburg. He has also worked in business roles for Ernst & Young Consulting and the Merckle/ratiopharm group in Germany and has represented the Diagnostics industry as an executive on the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Bruce is currently a Strategic Advisor to the Davos Alzheimer's Collaborative (DAC).

Sebastian Kohler Associate Professor Maastricht University

Seb is an Associate Professor of Neuroepidemiology at the School for Mental Health and Neuroscience and leads the research line Risk and Prevention of the Alzheimer Centre Limburg, both at Maastricht University. He conducts studies ranging from fundamental-epidemiological studies on risk factors and protective factors for cognitive decline and dementia to lifestyle-based intervention and implementation studies at the individual as well as population level. He and his team developed the Lifestyle for Brain Health (LIBRA) score, 'MijnBreincoach' app, and the public health campaign 'We are the medicine ourselves', which have all been successfully implemented in other national and international initiatives to improve brain health. He is the co-PI of the 2-year FINGER-NL trial (2020-2027), randomizing 1206 older adults into a multidomain lifestyle intervention program or control group. In the ABOARD consortium (2021-2026), Seb leads the work on dementia risk reduction in memory clinic patients, and he is the PI of the Netherlands Dementia Prevention Initiative (NDPI, 2022-2026), a national consortium for dementia risk reduction and part of the Dutch National Dementia Strategy.

Julija Krupic Assistant Professor University of Cambridge

My research is focused on studying the hippocampal-entorhinal function in health and disease using mouse models. In particular, I am interested in changes in hippocampal-entorhinal circuits and animal behaviour at the early stages of pathology. We use state-of-the-art in vivo 2 photon imaging and neurophysiological recordings in mice navigating virtual environments to study neural activity and how it supports spatial memory and navigation. Anastasia Krywonos FY2 Doctor Oxford University Hospitals NHS Foundation Trust I am a Foundation Year 2 Doctor with an interest in public health, psychiatry, and anthropology. Having completed my medical school at University College London (UCL), I am now based in Oxford and currently working on projects focused on dementia as part of my rotation in Public Health.

Anastasia Krywonos Doctor Oxford University Hospital

I am a Foundation Year 2 Doctor with an interest in public health, psychiatry, and anthropology. Having completed my medical school at University College London (UCL), I am now based in Oxford and currently working on projects focused on dementia as part of my rotation in Public Health.

Ben Lacey Senior Fellow UK Biobank and University of Oxford

Ben Lacey is a Senior Fellow at the Nuffield Department of Population Health, University of Oxford. He currently leads the UK Biobank Epidemiology Group, which supports the conduct and scientific enhancement of UK Biobank for researchers worldwide.

Louise Lafortune Senior Research Associate University of Cambridge

Experienced applied ageing researcher who embraces a global vision of public health to the development and evaluation of health interventions and policies adapted to demographic ageing, with frailty, dementia and age friendly communities as research focus areas.

Giovanna Lalli Director of Scientific Affairs Dementia Research Institute (DRI)

Giovanna Lalli is the Director of Scientific Affairs of the UK Dementia Research Institute (UK DRI - <https://ukdri.ac.uk/about-us>), working on strategic development and partnerships, scientific initiatives, training/career development activities. Giovanna holds MSc degrees in Chemistry and Pharmaceutical Technology (University of Bologna) and in Molecular Biology (University of Southern California). She obtained a PhD in Cell Physiology from University College London and has nearly 20 years of research experience, including a seven-year period as principal investigator and lecturer in molecular neurobiology at King's College London. Giovanna joined the UK DRI in September 2018, following three years as Senior Portfolio Developer at Wellcome overseeing the cellular and molecular neuroscience portfolio, supporting applicants and award holders, interacting with a wide range of UK and international stakeholders. While at Wellcome Giovanna also served for ten months as Acting Head of Neuroscience and Mental Health, developing new strategic funding initiatives in neuroscience research.

Roxanne Langlois Senior Director Business Development IXICO

Global business development executive with a track record of building pipelines, partnerships, and income across various industries within the healthcare sector including CROs, drug development, medical device, and public-private partnerships. Currently Senior Director Business Development at IXICO, an imaging CRO specialised in CNS disorders. Previously led Commercial Partnerships for Our Future Health, a UKRI backed initiative to build the UK's largest population cohort, which culminated in partnerships with 14 of the world's top global Pharma & Diagnostics companies.

Filipa Landeiro Senior Researcher in Health Economics University of Oxford

I am a health economist conducting work in the field of Alzheimer's disease. Roxanne Langlois Sr Director Business Development IXICO Global business development executive with a track record of building pipelines, partnerships, and income across various industries within the healthcare sector including CROs, drug development, medical device, and public-private partnerships. Currently Senior Director Business Development at IXICO, an imaging CRO specialised in CNS disorders. Previously led Commercial Partnerships for Our Future Health, a UKRI backed initiative to build the UK's largest population cohort, which culminated in partnerships with 14 of the world's top global Pharma & Diagnostics companies.

Lydia Lanman Senior Global Access Policy Lead Roche

Lydia Lanman is the Senior Global Access Policy Leader at Hoffmann-La Roche and is responsible for global health policy efforts in neuroscience, rare disease, immunology, ophthalmology and influenza. Her area of expertise is brain health and Alzheimer's disease. Lydia joined the pharmaceutical industry in Canada in 2007, where she led a variety of national policy, government relations and market access efforts at two pharmaceutical firms. Prior to joining pharma, Lydia worked in various senior advisory roles in Canada, providing strategic advice directly to Ministers and Deputy Ministers of Health, both federally and provincially, on the development of health care policy, health system design and intergovernmental relations. Lydia holds a Bachelor of Arts in Political Science and a Master of Arts in Political Science/Public Health, both from the University of Alberta. Her graduate work focused primarily on Canadian and international health care reform.

Jaffar Latif Policy Adviser Dementia Office for Life Sciences

Jaffar works in the UK's Office for Life Sciences on the development of the UK Government's recently announced Dementia Mission. This is one of the eight healthcare missions being tackled through the UK's Life Sciences Vision and Drugs Strategy, in collaboration with industry, academia, the third sector and the NHS. The Mission aims to improve translational capabilities in dementia and neurodegeneration by developing precision medicine tools that will help speed up clinical trials while improving accuracy and chance of success. Situated within a rich UK research ecosystem, the mission will build on existing UK and global dementia research initiatives and clinical research infrastructure.

Jo Latimer Head of Neurosciences and Mental Health MRC

Jo Latimer is Head of Neurosciences and Mental Health at the Medical Research Council, part of UK Research and Innovation. The Neurosciences and Mental Health Board aims to develop scientific knowledge that extends our understanding of disorders of the human nervous system such that new interventions and treatments can be developed. Jo has a PhD in Parkinson's Disease and has several years post-doctoral research experience in academia and the biotech sector.

Nathalie Le Bastard Marketing Manager Fujirebio

Nathalie started her career as a Neuroscientist in academic research. She obtained a PhD in Biomedical Sciences (Neurosciences) at the University of Antwerp, Belgium, in 2011. She joined Fujirebio Europe (formerly known as Innogenetics) in 2012 where she currently holds the role of Scientific Liaison in charge of the company's current Neurodegeneration product portfolio, as well as the preparation of novel, innovative solutions for Alzheimer disease testing. Strengthened by previous experiences in academic research (with over 35 peer-reviewed publications) and market development and education related to IVD products, she is today playing a central role in ensuring the market readiness from the IVD perspective in anticipation of a disease-modifying drug for Alzheimer.

Melanie Lee CEO LifeArc

Dr Melanie Lee is the CEO of LifeArc, a UK based medical charity focused on the translation of innovative new science into products and solutions for patients. The Charity forms the bridge between academia, charities and commercial organisations and offers scientific expertise and practical science, advice and funding. LifeArc also collaborates with MRC, DRI, CRUK and other partners to advance research findings into life changing solutions for patients. LifeArc partners with DRI for translation of science into solutions for patients including funding new companies.

Sen Liu Consultant Pason Pharmaceuticals

Dr. Sen Liu graduated from Xi'an Medical University in China and completed his residency as an ophthalmologist. After the fellow-ship training at Wills Eye Hospital of Thomas Jefferson University in USA, Dr. Sen Liu returned to China, and he have been working in the pharmaceutical industry. Dr. Sen Liu is one of the pioneers in China for the biomarker study for diagnostics of neurodegenerative diseases. He is also active in the field of new drug discovery for the treatment of neurodegenerative diseases. Dr. Sen Liu was also a member of China-Germany Biotechnology Steering Committee, and in the past six years, he has supervised several multi-center clinical studies on new biomarkers for early diagnostics of Alzheimer's diseases. Dr. Sen Liu is currently lead-ing an international team working on the development of new drugs for the treatment of Alzheimer's disease.

David Llewellyn Director and Professor University of Exeter

David works at the University of Exeter Medical School as the Director of Research and Impact at the Departments of Health and Community Sciences and Health and Care Professions, and is a fellow at the Alan Turing Institute. David's research focuses on combatting dementia and promoting brain health through data science and AI. He founded and leads the Deep Dementia Phenotyping (DEMON) Network, a global network of over 1,500 members. Additionally, he co-founded the Alan Turing Institute Interest Group in Precision Dementia Medicine and sits on the Steering Committee of the Early Detection of Neurodegeneration (EDoN) initiative. David is also an honorary contract holder with the Devon Partnership NHS Trust, and a member of the grant review board and clinical policy advisory panel of Alzheimer's Research UK. He has published over 100 articles in prestigious journals such as JAMA, Alzheimer's & Dementia, JAMA Psychiatry, Neurology, and the BMJ.

Simon Lovestone Global Lead Neuroscience Discovery and Translation Janssen

Simon Lovestone is a clinician scientist with a scientific background in Molecular Neuroscience and a clinical training in Old Age Psychiatry. He worked at the Institute of Psychiatry and the South London and Maudsley Hospital for close to 25 years including periods as Director of the SLaM Biomedical Research Centre and Director of R&D at King's Health Partners and also at the University of Oxford as Professor of Translational Neuroscience. He joined Janssen in 2014 heading up Neurodegeneration and is now responsible for Discovery and Translational work across Neurodegeneration and Neuropsychiatry. His own research focused on molecular mechanisms of disease including those related to tau, and on the genetics and then biomarkers of Alzheimer's disease. This research frequently employed bioinformatics and machine learning on very large data sets even though he was in the remedial stream for maths at school.

Miriam Lucar Research Assistant Universidad Peruana Cayetano Heredia Psychologist and Gerontologist
Research assistant in a project funded by NIHR focused on the assessment of dementia in Peru.

Jill Manthorpe Professor of Social Work Kings College London (KCL)

Prof Jill Manthorpe is Director of the NIHR Policy Research Unit in Health and Social Care Workforce at King's College London. She undertakes research on dementia care, workforce support and caregiving covering policy and practice. She publishes widely from her research and is involved in support for people living with dementia in a voluntary role. With the support of colleagues she has undertaken research on long-standing problems affecting people living with dementia and their carers as well as newly emerging challenges around Covid-19 and inequalities.

Olivia Marshall Public Affairs Manager Dementia Research Institute (DRI)

Olivia recently joined the UK DRI from the charity sector where she gained a wealth of experience in communications, policy and public affairs. She holds a masters in Public Health from King's College London and a BA in Music from the University of Cambridge.

Tetsu Maruyama Chief Scientific Officer Alzheimer's Disease Data Initiative (ADDI)

Tetsu Maruyama is the Executive Director of the ADDI, where he has the pleasure of working with an exceptional team to enable data relevant to Alzheimer's and related dementias to reach their full potential. Prior to joining ADDI, Tetsu was the Chief Scientific Officer at the Dementia Discovery Fund, a unique venture capital fund focusing a total investment of \$350 million on creating new treatment paradigms for dementia. Before that he was head of Drug Discovery for Takeda Pharmaceuticals in Japan, after leading the GlaxoSmithKline Centre for Cognitive and Neurodegenerative Disorders in Singapore. He began his industry career at Merck Sharp and Dohme's Neuroscience Research Center in the UK, after 15 years as an academic neuroscientist at Cardiff University and the University of Minnesota.

Ayami Matsumura Section Chief for Dementia Care Ministry of Health, Labour and Welfare (MHLW)

B.A., Health Science in Nursing, Tohoku University 2019 M.P.H., Tohoku University Graduate School of Medicine, School of Public Health PROFESSIONAL CAREER Aug 2022 Chief of Dementia Care Aug 2020 Chief of Training System for Nurses Pertaining to Specified Medical Acts Apr. 2020 Joined Ministry of Health, Labour and Welfare, Japan Apr. 2012 Registered Nurse Joined Tohoku University Hospital

Charlotte McIntyre Innovation Accelerator MHRA
Innovation Accelerator, MHRA.

Ruth McKernan Venture Partner SV Ventures

Ruth has over 25 years in the Pharma Industry at Merck and Pfizer, leading several Research Sites in the UK and US during her career. She has set up new Research Units, including Pfizer Regenerative Medicine and Neusentis, initiated multiple neuroscience partnerships, acquisitions and spinouts and played an active role in taking more than 10 compounds into the clinic. Immediately prior to joining SV, she spent 3 years as CEO of the UK Government's Innovation agency, InnovateUK, supporting the UK's Industrial Strategy with responsibility for investing an annual budget of £1Bn into Technology centres and SMEs. Outside of SV, Ruth is a trustee for Alzheimer's Research UK and Chair of the UK's BioIndustry Association. She is an enthusiast for innovation and entrepreneurship, sitting on multiple innovation and translation boards including the Academy of Engineering and the CRICK Institute.

Jaime Miranda Professor of Global Health Universidad Peruana Cayetano Heredia

J. Jaime Miranda, MD, MSc, PhD, FFPH, is Research Professor at the Department of Medicine, School of Medicine, and Director of the CRONICAS Center of Excellence in Chronic Diseases, both at Universidad Peruana Cayetano Heredia (UPCH) in Lima, Peru. His work brings together epidemiological and health policy aspects of chronic non-communicable diseases in low- and middle-income countries, with an emphasis on obesity, hypertension, diabetes, and mental health. In 2014, he was listed as one of the 30 scientists under 40 who are redefining science in the Latin American region. In 2018, his work was profiled in the scientific journal *Nature* as a “model of interdisciplinary research that is scarce in any part of the world.” Professor Miranda is currently serves as co-Chair of the Independent Group of Scientists (IGS) appointed by the UN Secretary-General in charge of the 2023 Global Sustainable Development Report. Professor Miranda trained in medicine at UPCH and earned a PhD in epidemiology at the London School of Hygiene and Tropical Medicine (UK). He holds appointments as Professor of Global Health at the London School of Hygiene and Tropical Medicine, Lown Scholar at the Harvard T.H. Chan School of Public Health (USA), and Distinguished Fellow at The George Institute for Global Health (Australia).

Susan Mitchell Head of Policy Alzheimer’s Research UK

Dr Susan Mitchell is Head of Policy, as part of the policy and public affairs team at the UK’s leading dementia research charity, with responsibility for developing evidence-based policy to ensure people affected by dementia benefit from the progress in research. Susan leads the charity’s policy development and engagement to improve early and accurate diagnosis for dementia, working with multiple stakeholders to develop an evidence base for the case for change. Susan has an ongoing interest in dementia risk reduction and brain health, leading Alzheimer’s Research UK engagement with policy makers to reframe dementia risk reduction as the concept of brain health.

Hans Moebius CMO Athira

Hans J. Moebius has served as Chief Medical Officer of Athira Pharma since 2019 and was part of its IPO in 2020. Beforehand, Hans co-founded Exciva GmbH, a biotech focusing on targeted drug rescue, and served as its CEO/CMO for 3 years, securing series A financing. His industry career started in 1991 at Ciba/Novartis headquarters. Ever since, Hans served in international leading pharma positions in neuroscience, which led to the approval of several new CNS therapies, most notably memantine in Alzheimer’s disease; he is the sole inventor of Namzaric® and co/inventor on several patents. - Hans earned his PhD in experimental pharmacology from the University of Heidelberg and is board certified in neurology and psychiatry.

Rosa Montesinos Psychiatrist Instituto Peruano de Neurociencias

A psychiatrist at Instituto Peruano de Neurociencias in Peru. She is a master in medicine and rehabilitation, member of the dementia research team in Peru, with particular interest in brief cognitive tests for the detection of cognitive impairment and dementia adapted for individuals with low educational level and illiterate urban and rural populations; as well as in indigenous populations (Quechua and Aymara). We conducted the first study of dementia prevalence in Peru.

Lauren Moore Dementia Mission Policy Advisor Office for Life Sciences

Lauren works in the UK’s Office for Life Sciences on development of the UK Government’s recently announced Dementia Mission. This is one of the eight healthcare missions being tackled through the UK’s Life Sciences Vision and Drugs Strategy, in collaboration with industry, academia, the third sector and the NHS. The Mission aims to improve translational capabilities in dementia and neurodegeneration by developing precision medicine tools that will help speed up clinical trials while improving accuracy and chance of success. Situated within a rich UK research ecosystem, the mission will build on existing UK and global dementia research initiatives and clinical research infrastructure.

Nula Moran Staff Writer BioWorld

Science Journalist covering the medical biotech sector in the UK and elsewhere in Europe for 30 years.

Laura Nisenbaum Executive Director, Drug Development Alzheimer’s Drug Discovery Foundation (ADDF)

Laura Nisenbaum, PhD, is a proven scientific leader with 30 years of biotechnology industry and academia experience. As Executive Director of Drug Development at the ADDF, she oversees the Scientific Affairs, Biomarker Development, and Aging and Alzheimer’s Prevention teams. Most recently, Dr. Nisenbaum served as Senior Director of Aducanumab Biomarkers and Diagnostic Pathways at Biogen, where she led the biomarker strategy for Aducanumab, as well as the Diagnostics Pathway group within the Biomarker Organization. Her time at Biogen followed 20 years of experience at Eli Lilly and Company where she served as Asset Manager for Chorus, an autonomous early-phase clinical development organization within Lilly. Dr. Nisenbaum also served as Research Fellow and neuroscience lead in tailored therapeutics, translational medicine, and preclinical drug discovery. Prior to joining the biotechnology field, Dr. Nisenbaum received a Fulbright Scholarship to study in Cologne, Germany. She then completed her PhD in neuroscience in 1991 at the University of Pittsburgh and transitioned to industry after completing postdoctoral training at the National Institutes of Health (NIH), the University of Tennessee College of Medicine, and a faculty position in Physiology and Neurobiology at the University of Connecticut. Throughout her career, Dr. Nisenbaum has contributed to the discovery and development of more than 15 novel therapeutics, bringing three molecules for FDA approval. She has also authored over 35 publications in peer-reviewed scientific journals.

Ryoji Noritake Director Health and Global Policy Institute (HGPI)

Mr. Ryoji Noritake is the CEO, Board Member of Health and Global Policy Institute (HGPI), a Tokyo-based independent and non-profit health policy think tank established in 2004. He was a member of Tokyo Metropolitan Government’s Policy Discussion Roundtable for Super Ageing Society (2018). He is a graduate of Keio University’s Faculty of Policy Management, holds a MSc in Medical Anthropology from the University of Amsterdam, the Netherlands. He is currently a Visiting Scholar at the National Graduate Institute for Policy Studies, a member of Salzburg Global Seminar’s Advisory Council and serves as a member for various ageing related committees in Japan.

Richard Oakley Head of Research Alzheimer's Society
Richard plays a critical role in the development and implementation of Alzheimer's Society's Research Strategy; working with the Director of Research and Influencing to lead our growing and ambitious world class research programme and portfolio. In particular, Richard heads up our Research Grants, Research Communications and Research Engagement teams. Together, they aim to ensure we provide essential funding and support to researchers, continue to engage people affected by dementia and communicate key milestones and developments in research across our networks and to the wider public.

John O'Brien Professor of Old Age Psychiatry University of Cambridge Department of Health Lead

John O'Brien is Professor of Old Age Psychiatry in the Department of Psychiatry at the University of Cambridge. He is a National Institute for Health Research (NIHR) Emeritus Senior Investigator and a Fellow of the UK Academy of Medical Sciences. He is the NIHR Clinical Research Network National Specialty Lead for Dementia. His main research interests are in the clinical and research application of imaging biomarkers in dementia, dementia with Lewy bodies and clinical trials. He has been a member of the National Institute for Health and Social Care Excellence (NICE), British Association of Psychopharmacology, European Federation of Neurological Sciences and European Stroke Association Dementia Guideline groups.

John O'Keefe Professor University College London

Researcher on the function of the Hippocampal Formation and its role in Alzheimer's Dementia Peter Paniccia
Caregiver Caregiver Peter retired from his life as a company owner manufacturing nationally renowned ice cream in 2007. Taking up photography as a hobby and becoming an official photographer for various local, national and international conferences. Husband and supporter of Hilary Doxford who was diagnosed with dementia in 2012. He is also a member of local and national dementia groups focusing on improving the lives of people affected by dementia.

Russ Paulsen Chief Operating Officer

UsAgainstAlzheimer's

Russ joined UsAgainstAlzheimer's as chief operating officer in 2019. Since then, the organization built a web and telephone platform that delivers information tailored to where a specific user is on their Alzheimer's journey; received its first-ever funding from the Centers for Disease Control and Prevention; and assembled a 100-organization coalition to set a US Alzheimer's risk-reduction goal. Prior to joining UsAgainstAlzheimer's, his team at the American Red Cross built a campaign to reduce deaths from home fires; it has saved more than 1200 lives since its launch and made 960,000 high-risk homes safer through smoke alarms and fire escape plans. More than 1.7 million kids have learned about fire safety through classroom presentations and an award-winning videogame designed by his team. And in the aftermath of Hurricane Katrina, in addition to rebuilding thousands of homes, Russ led a Red Cross team that helped rebuild the mental health system of coastal Louisiana and Mississippi through targeted grants and a system of treatment reimbursement that created an economic incentive for small providers to return. Russ's career in helping began with an earthquake in the San Francisco Bay Area, when he felt compelled to drop what he was doing and volunteer.

Jim Pearson Director of Policy and Research AlzScot
Jim is Alzheimer Scotland's Director of Policy & Research. He leads on all of Alzheimer Scotland's public policy development and campaigning. Jim is responsible for working with key stakeholders and other partners to ensure that the commitments of Scotland's National Dementia Strategy bring about transformational change for people with dementia, and those who care for them, across Scotland. He is also responsible for Alzheimer Scotland's national and local involvement networks ensuring that people with dementia and carers of people with dementia have an effective collective voice at a national, international and local voice to influence dementia policy, practice and research. Jim also leads Alzheimer Scotland's engagement in dementia research including the organisation's investments in research; building strategic partnerships with academic institutions; supporting participation in research; encouraging and facilitating collaboration and investment in Scottish dementia research; and the translation of research informed policy and practice. Jim is also leads Alzheimer Scotland's engagement with international partners including Alzheimer Europe and Alzheimer Disease International and is a former member of the Alzheimer Europe Board.

Peter Paniccia

Peter retired from his life as a company owner manufacturing nationally renowned ice cream in 2007. Taking up photography as a hobby and becoming an official photographer for various local, national and international conferences. Husband and supporter of Hilary Doxford who was diagnosed with dementia in 2012. He is also a member of local and national dementia groups focusing on improving the lives of people affected by dementia.

Robert Perneczky Head of the Alzheimer Treatment and Research Centre University of Munich

Robert Perneczky is Professor of Psychiatry at Ludwig-Maximilians-University (LMU) Munich and director of the Division of Old Age Psychiatry and the Alzheimer's Research and Therapy Centre at the LMU University Hospital. He is also Professor and director of dementia research at the University of Sheffield. Robert has 20 years of experience with translational dementia research, focusing on imaging and fluid biomarkers, neuroepidemiology and healthcare systems preparedness. He has a medicine and PhD degree from Technical University of Munich and an MBA degree from Warwick Business School. Micaela Pesantes Project Manager Universidad Peruana Cayetano Heredia Peruvian Project Manager for the Project IMPACT (Health Systems Innovations using Mhealth in People with dementia and Co-morbidities). Respiratory medic and PhD student.

Micaela Pesantes Project Manager IMPACT

Peruvian Project Manager for the Project IMPACT (Health Systems Innovations using Mhealth in People with dementia and Co-morbidities).

Timesh Pillay Imperial College London

Respiratory medic and PhD student.

Jo Pisani Trustee UK Dementia Research Institute

After a 30 year career in the Pharma and Lifesciences industry with GSK, Booz&Co and PwC I am now a non exec and chair of UK Lifesciences companies. I am a non exec director of the UK Dementia Research Institute, LifeArc and Beacon. I am chair of the Precision Health Technology Accelerator on Birmingham and interim chair of London's MedCity. I am a board member for startups in digital health, cell and gene therapy and medical devices. Richard Pither CEO Cytox Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer's disease patients.

Richard Pither CEO Cytox

Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer's disease patients.

Enea Polotti Sr Director EMEA Strategic Marketing Eisai Europe Ltd

Innovation that changes the future of patients is the purpose and the ultimate measure of impact. Currently Sr Director EMEA Strategic Marketing and Commercial Operations Dementia Franchise at EISAI, Enea has more than 20 years of experience in sales, marketing and product launch as Co-founder, Business Unit Head, Chief Commercial Officer, Commercial and Strategy leader in pharmaceutical and B2B health technology. Holds an MBA degree from SDA Bocconi and Duke Fuqua School of Business.

Shahmeen Rasul Junior doctor

Junior doctor in NHS.

Annemie Ribbens VP Science icometrix

Annemie Ribbens is Vice President Science, Evidence and Clinical Trials at icometrix. icometrix is world leader in bringing AI imaging solutions for neurology towards clinical practice, with a specific focus on quantitative image analysis. The icometrix' technology is used in clinical centers worldwide as well as in clinical trials and strategic partnerships with top 10 pharmaceutical companies. Annemie Ribbens has a strong research background in mathematical models for image-based patient stratification in neurology (Leuven, Belgium and London, UK). In 2014, she started as a senior researcher at icometrix where she co-developed the algorithm that forms the base of the current CE/FDA cleared icobrain portfolio for brain MRI quantification. Currently, she manages all scientific research operations at icometrix, generating evidence for the clinical, technical and health economic benefits of the icometrix' portfolio, and using the icometrix portfolio in phase I-IV clinical trials and real world evidence studies of top pharmaceutical companies to improve the safety and efficacy evaluation of novel drugs. Together with her team, she aims to drive the field of neurology forward in adopting AI solutions to improve patient care management and patient outcomes.

Alessandro Riccomben National Genomics Officer Microsoft UK

Dr. Alessandro Riccombeni is Microsoft's first National Genomics Officer, leading Microsoft's support for the United Kingdom's Precision and Genomic Medicine industry, across public and private sector. Alessandro was previously International Head of Precision and Genomic Medicine at Amazon Web Services, and Director of Business Development at DNAnexus. Alessandro holds a Ph.D. in Computational Infection Biology from University College Dublin, and an Executive MBA from London Business School.

Jill Richardson Head UK Neuroscience, Executive Director MSD

Dr. Richardson is currently an Executive Director, leading the U.K. Neuroscience Group at the London Discovery Research Centre. With over 26 years of leading drug discovery programmes and departments in the field of neuroscience, Dr. Richardson is now leading a portfolio of innovative drug discovery programmes with the aim of treating diseases of ageing with a focus on neurodegenerative diseases in the short term. She has also established a network of academic collaborations within the U.K. and Europe for MSD. With 125 peer reviewed publications, she is internationally recognised for her broad expertise in neuroscience research and drug discovery and has made important contributions to neurological diseases including Alzheimer's disease, multiple sclerosis, pain and epilepsy during her career in the pharmaceutical industry. She is a Fellow of the Royal Society of Biology and has a Visiting Professorship at Imperial College London. She serves on several national and international Advisory Boards including the Wellcome Trust, MRC DRI Quinquennial panel and ARUK DDI Review Panel.

Louise Robinson Professor of Primary Care and Ageing Newcastle University

Professor Dame Louise Robinson is an academic GP and Professor of Primary Care and Ageing at Newcastle University. She was the first GP to be awarded a prestigious NIHR Professorship. Professor Robinson also holds the first UK Regius Professorship in Ageing. Louise leads a research programme focused on improving quality of life and quality of care for older people, especially those with dementia. She leads 1 of only 3 Alzheimer Society national Centres of Excellence on Dementia Care. Louise was primary care lead for the Prime Minister's Dementia Challenge and is a member of the National Dementia Care Guidelines development group.

Mark Roithmayr Chief Executive Officer Alzheimer's Drug Discovery Foundation (ADDF)

Mark Roithmayr is Chief Executive Officer, and his primary focus is securing the resources needed to find effective drugs for Alzheimer's disease. Mr. Roithmayr is a seasoned nonprofit executive with experience in both start-ups and mature organizations. His areas of expertise include strategic planning, fundraising, volunteer development, and brand-building. He has helped to increase the ADDF's revenue three-fold to \$60 million and was instrumental in securing Bill Gates, as well as Jeff Bezos and MacKenzie Scott, as donors to the organization's venture philanthropy efforts.

Mr. Roithmayr was previously Chief Relationship Officer at the Leukemia and Lymphoma Society. There, he helped launch its venture philanthropy initiative, directed its 56 national chapters, and led annual fundraising of over \$200 million. Prior to joining the Leukemia and Lymphoma Society in 2013, he served for seven years as president of Autism Speaks. As that organization's first president, he shepherded its growth from a start-up into the world's largest autism research and advocacy organization. During his tenure, Autism Speaks invested more than \$170 million in research, resulting in discoveries about the genetic and environmental factors that lead to autism as well as effective treatments for it. Earlier in his career, Mr. Roithmayr held several executive positions with the March of Dimes. He earned a bachelor's degree in communications at Rowan University.

Jane Rylett Scientific Director Institute of Aging (CIHR)

Dr. Rylett is a Distinguished University Professor at the University of Western Ontario, Canada and Scientist in the Translational Neuroscience Group at Robarts Research Institute. She is past-Chair of the Department of Physiology and Pharmacology at the Schulich School of Medicine & Dentistry and served as an Associate Dean. She is currently the Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Aging. She is a cellular and molecular neurobiologist studying consequences of age-related changes in brain and neurodegenerative diseases. She is recognized internationally for contributions in studies on cholinergic neurobiology and Alzheimer disease. Dr. Rylett has served on Boards of Directors of the Alzheimer Societies of Canada and Ontario, and on taskforces for international endeavours for Alzheimer Disease research. She was also leader of the Canadian Consortium on Neurodegeneration in Aging (CCNA) Theme 1, and appointed as an inaugural College Chair of the CIHR College of Reviewers and held the position of Executive Vice-Chair. She is a Fellow of the Canadian Academy of Health Sciences.

Takahiro Sakauchi Senior Associate Health and Global Policy Institute (HGPI)

Mr. Takahiro Sakauchi holds a Bachelor of Science in Sports Science degree from Waseda University and is a certified athletic trainer. While attending Waseda University, he gained clinical experience at the Waseda Sports Medicine and Science Clinic, where he provided support to the university's sports clubs, as well as at Stanford Sports Medicine. After graduation, he pursued his enthusiasm for sports healthcare and rehabilitation in various settings including Dublin City University Sports Clinic in Ireland, GPS Rugby Club in Australia, and Central United / Auckland City FC in New Zealand. Working in countries with different health systems from Japan made him interested in health policy and led him to join HGPI in January 2020. Projects he currently serves on include the Innovation and Sustainability Project, the Mental Health Policy Project, and Health Policy Academy. He also is currently pursuing a Master of Public Health degree at Glasgow Caledonian University and is working part-time at a rehabilitation clinic.

Steve Salloway **Martin M. Zucker** Professor of Psychiatry and Human Behavior, Professor of Neurology Kent Hospital Rhode Island

Stephen Salloway is Associate Director of the Brown Center for Alzheimer's Disease Research, the founding Director of the Memory and Aging Program (MAP) at the Butler Hospital, a Professor of Neurology and the Martin M Zucker Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University, Providence, RI. Professor Salloway's research focuses on biomarker and drug development for prevention and early treatment of Alzheimer's disease, particularly the use of positron emission tomography (PET) ligands, plasma and CSF biomarkers for amyloid and tau to study the evolution of Alzheimer's pathophysiology in autosomal dominant and sporadic Alzheimer's disease. The MAP also has a lead role in testing targeted treatments, such as monoclonal antibodies, antisense oligonucleotides and novel anti-inflammatory agents. Professor Salloway serves on the steering committees for the National Institutes of Health Alzheimer's Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer Network, and the Alzheimer's Clinical Trial Consortium. In 2023, he was chosen as the recipient of the Leon Thal Award for Alzheimer's Research from the Cleveland Clinic Lou Ruvo Center for Brain Health, an award named to honor the memory of Dr. Leon Thal, a pioneering neurologist and neuroscientist and influential leader in the field of AD research.

Melanie Saunderson Office Manager World Dementia Council

Melanie is the Office Manager of the World Dementia Council, responsible for the administration of the charity, including finance and project management. She provides executive assistance to the Executive Director. Melanie is legally trained and has had a varied career in finance, property and senior executive administration. She has worked for The Crown Estate, The US Embassy in London, Department for Transport and Richard Green Art Gallery in Bond Street London. She is a fellow of the Institute of Administrative Management.

Vreni Schoenenberger Global Head of Public Affairs
Novartis

Dr. Vreni Schoenenberger is the Global Franchise Head, External Affairs and Partnership Strategy at Novartis, where she oversees external market shaping and global partnerships for its \$5B neuroscience portfolio. Additionally, Vreni serves as a board advisor to health ventures and sits on Oxford and Imperial's accelerators, and currently chairs the industry board of the European Brain Council. During her tenure at Novartis, Vreni has launched 5 products, including several blockbusters; spearheaded first-of-their-kind neuroscience initiatives at the WEF and G20; helped pass the first WHO Global Action Plan on Neurological conditions; and established the Novartis Innovation Prize in partnership with Sequoia, Airbnb, Microsoft, Uber and SXSW. She came to Novartis with a 15 year track record in the public sector, spanning pandemic response at the WHO; global health policy at the NIH; and work at the global biopharma trade group (IFPMA), where she oversaw partnerships with the U.N. Before this, she spent several years working on behalf of Yale University's \$45B endowment. Vreni holds a Ph.D in Modern History and Policy from Yale, where she was a Fulbright and MacMillan Scholar. She earned a B.S. in Bioethics, summa cum laude, from Vanderbilt University, where she was an Ingram Scholar.

Jonathan Schott Professor of Neurology at the Dementia
Research Centre, UCL Institute of Neurology; and
Honorary Consultant Neurologist at Queen Square

He co-leads the mental ageing programme of the MRC British 1946 birth cohort. His clinical and research interest centre on the dementias, with particular interests in how clinical and cognitive data, imaging and fluid biomarkers, and genetics can be used and combined to improve differential diagnosis and identify pre-symptomatic dementia. He has published over 320 papers on dementia and ageing. He is an MRC Investigator, Clinical Advisor to the UK Dementia Research Institute, and Chief Medical Officer for Alzheimer's Research UK.

Gustavo Sevlever Professor of Pathology FLENI

Dr Gustavo Sevlever MD. Ph.D., Faculty of Medicine University of Buenos Aires 1979; 1992 Director of Teaching and Research at the Fleni Institute Head of the Department of Neuropathology at the Fleni Institute Director of the Argentine Brain Bank. Chairman of the Ethics Committee of the Fleni Institute Director of the LIAN (Laboratory of Applied Research in Neurosciences). Councillor, International Society of Neuropathology Member de ISSCR Inquiry Review Panel (International Society for Stem Cell Research) Director of the Fleni-CONICET Institute (I-Neu) Authorized teacher (Pathology, Faculty of Medicine University of Buenos Aires Editor-in-Chief Lancet Neurology Spanish edition Reviewer on Case Reports in Neurological Medicine Journal of Alzheimer's Disease Movement Disorders Clinical Practice Lancet Neurology Lancet Global Health Frontiers in Neurology Researcher: 1. CICEMA (Argentine Stem Cell consortium) y PLACEMA (Stem cell platform) 2. Principal Investigator E-tumor (European Project) 3. Principal Investigator ADNI Argentina (Alzheimer Disease Neuroimaging Initiative) (<http://adni.loni.usc.edu/>) 4. Member of the advisor Committee in cell therapies and stem cells, Ministry of Science, 5. National coordinator, Bi national program (Argentina-Brasil) for Cell therapies. 6. DIAN (<https://dian.wustl.edu/sobre-nosotros/?lang=es-xm>) 7. FINGERS (<https://www.fingers.com/>) 8. LEADs (<https://leads-study.medicine.iu.edu/>) Interest: dementia, brain bank, biomarkers, stem cell biology, brain tumors, prognostic markers, genomics and taxonomy, bioinformatics in the diagnosis of brain diseases. 146 scientific papers in peer-reviewed international journals and 9 awards.

Samir Sinha Director of Geriatrics Mount Sinai Hospital

Dr. Samir Sinha is the Director of Geriatrics at Sinai Health System and the University Health Network in Toronto and a Professor of Medicine at the University of Toronto and the Director of Health Policy Research at Ryerson University's National Institute on Ageing. A Rhodes Scholar, Dr. Sinha is a highly regarded clinician and international expert in the care of older adults. He is the Architect of the Government of Ontario's Seniors and Dementia Strategies and in 2014 Canada's Maclean's Magazine proclaimed him to be one of Canada's 50 most influential people and its most compelling voice for the elderly. Dr. Sinha currently serves as a member of the Government of Canada's National Seniors Council and Ministerial Advisory Board on Dementia and is also leading the development of new National Long-Term Care Standards for Canada.

Sudhir Sivakumaran Vice President, Neuroscience Program, Executive Director, CPAD & Interim Executive Director C-Path

Sudhir Sivakumaran, PhD, serves as the Vice President of the Neuroscience Program, Executive Director for the Critical Path for Alzheimer's Disease (CPAD) consortium, and the Interim Executive Director for the Huntington's Disease Regulatory Science Consortium (HD-RSC) at The Critical Path Institute (C-Path). Dr. Sivakumaran oversees the overall strategic planning, management and execution of the strategic objectives and goals of the Neuroscience Program and the individual consortia. Dr. Sivakumaran also leads the C-Path Industry Data Sharing Initiative aimed at acquisition and management of CDISC standardized high-relevance clinical trial and observational study datasets in Alzheimer's disease. Together with the Quantitative Medicine Program at C-Path, Dr. Sivakumaran leads our efforts in the generation of novel regulatory-endorsed drug development tools (DDTs) by fostering relationships and engagement with industry, regulatory agencies (FDA, EMA) and patient advocacy organizations. The DDTs are intended to accelerate drug development by facilitating effective evaluation of drug efficacy and safety by optimizing novel clinical trial design and advance our understanding of disease progression. Dr. Sivakumaran brings around 20 years of combined academic and industry scientific and management experience with expertise in neurodegeneration and neuropsychiatric disorders such as Epilepsy, Stroke, Alzheimer's, and Autism. In addition to a bachelor and master's degree in microbiology obtained from the University of Madras, India, he holds a PhD in Neuroscience from SISSA/ISAS, Trieste, Italy.

John Skidmore CSO, ALBORADA Drug Discovery Institute University of Cambridge

Dr John Skidmore is the Chief Scientific Officer of the ALBORADA Drug Discovery Institute (ADDI) where he leads a group taking exciting new academic science and translating it into treatments for the diseases that cause dementia. Dr Skidmore's background is in Drug Discovery, during 8 years spent at GlaxoSmithKline he helped discover a number of molecules ready for clinical trials and whilst at the University of Cambridge he pioneered approaches towards developing a new class of drugs that work by disrupting the interactions between pairs of proteins that together cause disease. The ADDI is funded by Alzheimer's Research UK and collaborates with academics from the UK and around the world as well as with a number of biotech and pharma organisations.

Dirk Smeets CTO icometrix

Dirk Smeets is the current Chief Technology Officer. After his studies as biomedical engineering and a PhD in medical image analysis, he started at icometrix to lead the research and development. Driven by helping patients with neurological conditions, Dirk and his team have developed digital tools for an improved diagnosis and follow-up of patients with MS, dementia, TBI, epilepsy and stroke. Besides his role at icometrix, Dirk is also expert reviewer for the European commission, a visiting research at the universities of Brussels and Antwerp.

Adam Smith Programme Director University College London (UCL)

Adam Smith is a Programme Director at University College London, within the Queen Square Biomedical Research Centre. Adam has over 25 years' experience leading healthcare and research improvement initiatives within the NHS and Department of Health, and has been focussed on dementia for the past 11 years. His work has included creating Join Dementia Research a public engagement and study recruitment service and work to increase care home residents participation in research. He currently leads some of the UKs efforts to improve support for early career dementia researchers, aiming to change research systems and culture, and attract and retain people within the field, across all areas of discovery. Adam writes blogs, hosts podcasts and is Chair of the Alzheimer's Association ISTAART PIA to Elevate Early Career Researchers, he holds an honorary position at University of Sydney and sits on the UK Health Research Authority National Research & Ethics Advisors' Panel.

Ian Smyth Director Mednet Group

Ian Smyth – Founder of the Dementia Industry Group Ian held senior roles in the health sector including, Global Commercial Director for Johnson and Johnson Healthcare Innovation (JHI). Ian was seconded by the ABPI to a role as Deputy Director at the Office for Lifesciences to support the UK prime minister (David Cameron) in the field of Alzheimer's disease. In his role as Commercial Director for Janssen Healthcare Innovation (JHI) he led on developing cutting edge solutions through a global entrepreneurial team within Johnson and Johnson to modernise healthcare delivery and improve patient care. As Director for the Office for Life Sciences and the Department of Health he led on developing UK recommendations in Dementia for the UK Prime Minister.

Corinna Sorenson Professor & Director Duke University

Corinna Sorenson, PhD, directs the Margolis Scholars Program in Health Policy and Management. She also co-leads a number of the Center's educational initiatives. Dr. Sorenson has extensive research and policy expertise in value assessment in health care, comparative effectiveness research, drug and device regulation and payment, and health policy evaluation. She is interested in the design, implementation, and assessment of innovative, evidence-based strategies to enhance value-based health care, particularly with regards to new and existing health care treatments and services. In this work, she also examines the economic, methodological, political, cultural, organizational, professional, and legal levers that support or hinder the adoption of such approaches.

Aimee Spector Professor of Old Age Clinical Psychology
University College London (UCL)

Aimee Spector is Professor of Old Age Clinical Psychology. She co-developed Cognitive Stimulation Therapy (CST) for her PhD (completed in 2001), now widely implemented across the NHS and globally. Her expertise lies in the global development and evaluation of complex interventions for dementia. This includes currently being PI for 'CST-International' in Brazil, India and Tanzania and holding a UCL-PKU (Peking University) Global Engagement award. She directs the International CST centre at UCL, working with over 34 countries; and supports CST training centres in Hong Kong, the US, Denmark, Norway, Germany and New Zealand. Her research includes the evaluation of a range of interventions for dementia including Cognitive Behavioural Therapy, Compassion Focused Therapy and Mindfulness. She has published over 140 peer-reviewed papers, 4 book chapters and 10 books. She is international lead for University College London's Clinical Psychology doctorate course. Louisa Stevenson Public Affairs Director Eli Lilly Director of Public Affairs for Lilly in Northern Europe; leading company Communications and Government Affairs functions and working across all company therapy areas and pipeline assets.

Louisa Stevenson Director of Public Affairs Lilly
Director of Public Affairs for Lilly in Northern Europe; leading company Communications and Government Affairs functions and working across all company therapy areas and pipeline assets.

Jina Swartz Chief Medical Officer of an emerging biotech
Exciva; Academy of Medical Sciences

Dr Jina Swartz trained in Internal Medicine and Neurology in South Africa, obtaining her MBCh (MD) degree cum laude, followed by an MSc Medicine (Neurology). After the award of a post-doctoral research fellowship in 1998, she completed a PhD at the University of Cambridge, exploring molecular mechanisms of neurodegeneration in Huntington's disease and trinucleotide disorders. She is also a Fellow of the Academy of Medical Sciences. Jina possesses internationally recognised expertise in Neuroscience drug development, including Alzheimer's disease, related dementias, Parkinson's disease, schizophrenia, cognitive dysfunction, pain, multiple sclerosis and epilepsy. As well as ten years in academic Neurology practice and research, she has twenty years' experience in Clinical Development spanning exploratory research, Phase I, II and III global programmes through to drug registration. Jina also holds expertise in rare neurological diseases. Jina is currently Therapeutic Area Head of Neuroscience in Global Clinical Drug Development EMEA at MSD. She leads Clinical Development, Regulatory, Policy, Commercial, Operational, Business Development and Market Access activities across the EMEA region and is the clinical lead on global programmes in treatment resistant depression and Alzheimer's disease. An expert in Alzheimer's disease drug development, having led Eisai's donepezil programme, she joined Merck to coordinate the development of verubecestat in AD. Jina recently led the Alzheimer's "What if" Policy Roundtable sessions at the European Parliament, influencing policy change in EU dementia strategy.

Emily Teller Director of Communications and
Engagement UK Dementia Research Institute

As the Director of Communications and Engagement it is my role to raise the profile of the UK DRI and discovery science more broadly, showcasing the research that is happening across the UK's national Institute to fill the critical knowledge gap that will enable new treatments and care for people living with dementia, and ensuring policy officials and decision makers are kept informed and engaged with our work.

David Thomas Head of Policy, Access and Innovation
Alzheimer's Research UK

David Thomas leads Alzheimer Research UK's policy work on research funding and innovation as well as enabling access to new treatments. He is also chair of the Charity Medicines Access Coalition which works to shape national medicines access policy. Before joining Alzheimer's Research UK he led Roche's public affairs and policy work in the UK, including on dementia. David was also chair of the Dementia Industry Group. David has worked in healthcare for most of his career and is passionate about the interplay between science and public policy.

Victoria Tischler Professor of Behavioural Science
University of Surrey

Professor Tischler is Professor of Behavioural Science at University of Surrey. She is a Chartered Psychologist and Associate Fellow of the British Psychological Society. She holds honorary positions at both the University of Nottingham and University of Exeter Medical Schools. Her research interests include creativity and mental health and multi-sensory interventions in dementia care, with a focus on olfaction. She is co-executive editor of the journal Arts and Health: an international journal for research, policy and practice. She has worked as a curator in the outsider art field, she serves on the scientific advisory board for Boots UK archive.

Maria Tome Senior Scientific Officer European
Medicines Agency

Dr. Tome serves as Senior Scientific Officer at the Product Development and Scientific Support Department of the European Medicines Agency (EMA). EMA can provide medicine developers advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. EMA provides scientific advice and qualification of novel methodologies to support the timely and sound development of high-quality, effective and safe medicines, for the benefit of patients.

Dominic Trépel Assistant Professor (Health Economics)
Trinity College Dublin

Dominic Trépel (PhD) joined Trinity in 2017 as an Assistant Professor of Economics and is jointly appointed as faculty for the Global Brain Health Institute (www.gbhi.org) and Trinity School of Medicine. Trépel is also primary investigator in Trinity College Institute of Neuroscience (TCIN) where he directs Trépel lab (www.healthconomics.ie). Trépel has been an academic health economics for over 15 years, has published over 100 research articles and much of this research efforts are dedicated to the study of dementia, brain health and ageing. Trépel lab currently includes ten PhDs and Postdoctoral researchers working on grants funded by: Health Research Board (HRB), Irish Research Council (Ireland), Research Collaborative in Quality and Patient Safety (RCQPS), Health and Social Care Northern Ireland (R&D Division), Global Brain Health Institute, Brainlat and National Health and Medical Research Council (NHMRC).

Mike Turner Principal Business Advisor SAS Institute
I have been working as an advisor and consultant for over 30 years and for the last 5 years have been working with life sciences and health care organizations looking at problems in the mental health, diabetes, oncology, and vaccine arenas. Most recently working with identification and support mechanisms for health care professionals who are suffering early indications of 'burnout' and looking at 'waiting well' strategies for patients who are caught in the treatment backlogs as a knock-on effect of the global pandemic.

Silar Ultanir Group Leader Francis Crick Institute
I am a kinase expert and cellular neurobiologist. I am interested in dementia and signaling associated with neurodegeneration.

Cornelia van Duijn Professor of Epidemiological Oxford University
Cornelia van Duijn is a full professor of Genetic Epidemiology at the Nuffield Department of Population Health, University of Oxford and a Fellow of St Cross College, University of Oxford. Her research portfolio includes proteomic and metabolomic studies as key intermediate players linking the human genome, medication and lifestyle to Alzheimer's disease and related disorders. She is a leader in several international genome wide association consortia such as CHARGE (Cohorts for Heart & Aging Research in Genome Epidemiology), ENGAGE (European Network for Genetic and Genomic Epidemiology), EAGLE (Early Genetics and Life Course Epidemiology), IGAP (International Genomics of Alzheimer's Project) and IGGC (International Glaucoma Genetics Consortium). Over the years, she has also served on various European/global scientific committees; these include the ERC (European Research Council) Advanced Expert Committee, the European Society for Human Genetics (ESHG), the European Molecular Epidemiology Group, and the International Society for Genetic Epidemiology (IGES). For her work on Alzheimer's disease, she received a Pioneer Award from NWO/ZonMw in 1998. Over the years, she has published over 1000 scientific papers and supervised 45 PhD students. Her group aims to bridge the gap between genetic- epidemiologic and cellular model research. At present, she is the leader of two major consortia: the Horizon2020 CoSTREAM consortium aiming to understand the link between stroke and Alzheimer disease and the Dutch ZONMW MEMORABEL Gut-Brain consortium aiming to unravel the role of the gut microbiome in Alzheimer disease and brain pathology.

Wim van Heck CEO icometrix
Wim Van Hecke, PhD, is the founder and CEO of icometrix, a world leader in AI solutions to help people with neurological disorders. The fully automated icobrain software obtains clinically meaningful data from brain MRI and CT scans, is FDA/CE cleared and is used in a large amount of hospitals worldwide. In addition, icometrix works with the largest pharmaceutical and health tech companies. Wim is an academic engineer by training with two Master degrees in applied biomedical engineering and neuroimaging, and a PhD in diffusion MRI analysis. He is the author of more than 250 scientific publications and the editor of a clinical neuroimaging handbook. He's also a visiting professor at the free university of Brussels.

Peter Varnum Secretariat Davos Alzheimer's Collaborative
Peter Varnum is a Director for High Lantern Group. He built and led the World Economic Forum's work on global mental health from 2017-20, focusing on youth, technology, and the workplace. He also led the launch of the Davos Alzheimer's Collaborative (DAC) from WEF's side. From 2020-22, Peter was an Associate Director for Orygen, an Australian organization with three decades of world-leading expertise in youth mental health. He has worked with the World Health Organization, UNICEF, the civil society sector, and countless inspiring individuals. Peter is on the Board of The Stability Network, a US-based nonprofit organization made up exclusively of People with Lived Experience of mental ill-health. "Stability Leaders" share their stories to eliminate stigma of mental ill-health in all communities. Peter earned a BA in English from Carleton College in Northfield, Minnesota, and an MA in Law and Diplomacy from The Fletcher School at Tufts University in Medford, Massachusetts. In 2019, he completed the World Economic Forum's Global Leadership Fellows executive education program. Peter loves language, people, and the feeling of fresh air against his face. He lives with his family in Geneva, Switzerland.

Zoran Vasic Business Development and Regional Sales Director Fujirebio
Europe Business Development and Regional Sales Director.

Elisabetta Vaudano Principal Scientific Manager Innovative Health Initiative (IHI)
Elisabetta Vaudano is Principal Scientific Manager and portfolio manager for the neuroscience area at the Innovative Medicines Initiative (IMI) the largest European Public Private partnership in Health Sciences (budget > 5 billion EUR). Elisabetta is Italian, trained in Italy and UK and worked thereafter in UK, Sweden, Denmark and Belgium. Elisabetta is a doctor in veterinary medicine, a PhD in neuroscience and an MSc in Laboratory Animal Science. Elisabetta has a solid scientific background acquired in the 10years she worked as scientist in prestigious academic institutions in England and Scandinavia. Elisabetta has also large experience R&D and in scientific management in the private sector, via a series of positions at increasing level of responsibility in the pharma industry and in biotech in Denmark. Elisabetta joined IMI in 2010 and has a deep experience in alliance management, stakeholder engagement across the public-private spectrum, fostering and setting up of public-private partnerships, management of complex and large international research consortia and last but not least on funding mechanisms and processes and administration of European Research programmes.

Everard (Jort) Vijverberg Neurologist Alzheimer Center
As the part of the Alzheimer Center Amsterdam and Neuroscience Amsterdam, I have dedicated my career to find novel ways to treat Alzheimer's disease and other dementias. I'm founder of the CNS target and drug discovery center in Amsterdam UMC and PI of many sponsor/investigator initiated clinical trials.

Myrra Vernooij-Dassen Professor Emeritus Radboud University Medical Centre

Professor Myrra Vernooij-Dassen has been involved for many years in psychosocial intervention research in dementia. She has been trained as a medical sociologist and was director of the Radboud Alzheimer Centre. She is affiliated to the Scientific Institute of Quality of Healthcare of the Radboud University Medical Center in Nijmegen, the Netherlands and is visiting professor at the Gadjah Mada University in Yogyakarta, Indonesia and Bradford University UK. She is chair of INTERDEM, a pan-European research network on detection and timely INTERvention in DEMentia. She is chairing the IPA webinar series. She is a member of the Scientific Advisory Board of the European Joint Programme Neurodegenerative Diseases (JPND). She is guest editor of a special issue on social health for International Psychogeriatrics. She supervised 32 PhDs. She published more than 250 (inter)national peer reviewed articles. Professor Vernooij-Dassen Myrra received the Dutch royal honor to be promoted to officer in the order of Orange-Nassau. She received the IPA 2016 distinguished service to the field psychogeriatrics award. Her Scopus H-index is 46. Everard (Jort) Vijverberg Neurologist and Senior Researcher Amsterdam University Medical Center As the part of the Alzheimer Center Amsterdam and Neuroscience Amsterdam, I have dedicated my career to find novel ways to treat Alzheimer's disease and other dementias. I'm founder of the CNS target and drug discovery center in Amsterdam UMC and PI of many sponsor/investigator initiated clinical trials.

Kosuke Wada Director for Dementia Strategy, Division of Dementia Policy and Community-Based Long-Term Care Promotion, Health and Welfare Bureau for the Elderly, MHLW Ministry of Health, Labour and Welfare (MHLW)

Kosuke Wada is responsible for Dementia strategic policy in Japan, especially for total action plan for Dementia. Inclusion, risk reduction and promoting reserach for total dementia policy from 2022. 2014-2017 working in the UK for international cordination.

Wendy Weidner Research and Policy Project Lead Alzheimer's Disease International (ADI)

Wendy Weidner is the Research and Policy Project Lead for Alzheimer's Disease International (ADI) where she leads ADI's involvement in the STRiDE (Strengthening responses to dementia in developing countries) project in partnership with London School of Economics (LSE) to build research capacity and provide evidence to help improve dementia care, treatment and support in seven countries in Africa, Asia, and the Americas. Working alongside local policy makers, stakeholders, Alzheimer associations, and researchers to support the development of national policies for dementia, her role also focuses on implementation research to ensure sustainability and impact. Wendy leads on the development and growth of ADI's global research portfolio in partnership with academic institutions and Alzheimer associations across a wide range of projects including diagnosis, dementia care pathways, interventions, clinical trials and epidemiology. Wendy also coordinates and works alongside ADI's Medical and Scientific Advisory Panel, a diverse group of dementia specialists who provide expert advice to ADI.

Ben Williams Project Lead Care City

Ben is an experienced project lead managing complex, cross partnership programmes and projects in the health and social care industry. He has expertise in dementia, older people's housing, mental capacity, safeguarding and care standards. He does public speaking arrangements on dementia. Ben joined Care City in 2019 and has worked on managing health innovation integration for social care, the NHS, Local Authorities and Integrated Care Boards. He was part of the committee that wrote the national NICE dementia guidance NG97. He is currently completing a service evaluation of dementia services in London with the London dementia clinical network.

Julie Williams Professor Cardiff University

Julie Williams is a senior figure in the field of Alzheimer's disease (AD) research, was honoured as a commander of the British Empire (CBE) in the 2012 Queen's Jubilee Birthday Honour list for her research on Alzheimer's disease and was subsequently (2013) appointed Chief Scientific Advisor to the Welsh Government (2013-2017). Julie co-leads an international collaboration (IGAP) which has played a pivotal role in the find of 75 susceptibility genes for AD. She is now the Director of UK Dementia Research Institute at Cardiff and has built a research group of over 100 scientists to build upon the strong genetic evidence in Alzheimer's, Parkinson's and Huntingdon's diseases, to understand disease mechanisms and identify targets for therapeutic modification.

Appendix - post design registrations

Elisa Aguzzoli Research Assistant LSE

My name is Elisa Aguzzoli and I come from Italy. I have recently graduated from Brunel University where I obtained a degree in Anthropology. Now, I am doing my Master's in Global Health Policy at the LSE. In the meanwhile, I am working as a Research Assistant at CPEC, Care Policy Evaluation Centre and I am collaborating to several research projects such as STRiDE International and the Women's Brain Project. My research field mainly involves mental illnesses and my main focus area is dementia.

Jerome Burne Daily Mail

Medical and health journalist writing for national publications since 2000, mostly Daily Mail. Co-written several books with Patrick Holford, founder of charity Food for Brain that is developing a new protocol to reduce the risk of Alzheimers. Titles include Food is Better medicine than Drugs. Internet: <http://healthinsightuk.org>

Sophie Delamothe Research Policy Manager Department of Health and Social Care United Kingdom

Sophie Delamothe is a Research Policy Manager in the Science, Research & Evidence Directorate at the Department of Health and Social Care, primarily working on dementia and neurodegeneration research.

Andrew Morris Director Health Data Research UK

Professor Andrew Morris became the inaugural Director of Health Data Research UK in August 2017. He is seconded from his position as Professor of Medicine, and Vice Principal of Data Science at the University of Edinburgh, having taken up position in August 2014. Prior to this, Andrew was Dean of Medicine at the University of Dundee. Andrew was Chief Scientist at the Scottish Government Health Directorate (2012-2017) and has served and chaired numerous national and international grant committees and Governmental bodies. His research interests span informatics and chronic diseases. He has published over 330 original papers, attracted over £50 million in grant funding and was the principal investigator of several programme grants including the Wellcome Trust United Kingdom Case Control Collection for Type 2 Diabetes, Generation Scotland, a study of the genetic health in 50,000 Scots, the Wellcome Trust funded Scottish Health Informatics Programme (SHIP), and the Farr Institute in Scotland. In 2007 he co-founded Aridhia Informatics, which uses high performance computing and analytics in health care. Andrew was previously Governor of the Health Foundation (2009-2017), a leading UK charity that supports quality improvement in health care, and chaired the Informatics Board at UCLPartners, London (2014-2017). He is a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences.

Nadeem Sawar Global Head, Digital Eisai

Nadeem's expertise stems from the intersect of genomics, data science and digital technologies to drive therapeutic innovation.

Magdalena Walbaum Research Officer LSE

Dr Magdalena Walbaum is a researcher at the Care Policy and Evaluation Centre, London School of Economics and Political Science (CPEC LSE). She holds an MSc in Cardiorespiratory rehabilitation from University College London (UCL), an MSc in Health Economics from University of York and a PhD in Epidemiology, Public Health and Health Economics from UCL. Her work focuses on the economic impact of mental health and long-term conditions, and economic evaluations of interventions in health and social care. Prior to joining CPEC, she worked for the Department of non-communicable diseases at the Ministry of Health in Chile, focusing on the development of national guidelines and policies, and evaluating the implementation of national programmes for chronic conditions.

The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

worlddementiacouncil.org

© 2023 World Dementia Council
UK charity registration number: 1170743

